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Introduction 
 
 
 
 
 
 
 
Macrophage activation syndrome (MAS) is a severe and potentially life-threatening complication 
of many systemic diseases that shows a particular association with Systemic Juvenile Idiopathic 
Arthritis (sJIA). MAS belongs to the spectrum of Hemophagocytic Lymphohistiocytoses (HLH), a 
group of both genetic and acquired conditions characterized by an hyperinflammatory status 
driven by the uncontrolled secretion of pro-inflammatory cytokines due to the proliferation of 
activated lymphocytes and histiocytes1.  
This systemic, widespread inflammation can result in a wide range of clinical manifestations and 
laboratory abnormalities, including – but not limited to - hyperferritinemia, pancytopenia, liver 
and coagulation dysfunction and central nervous system involvement. In the most severe 
patients, renal, pulmonary and cardiac involvement may occur, leading to multiple organ failure 
and, eventually, to a fatal outcome2.  The clinical course of these patients can in some cases be 
rapid or fulminant and is generally hardly predictable. Moreover, the grade of organ involvement 
and clinical and laboratory manifestations are highly heterogenous3.   Despite the recognized 
 
1 Minoia, Francesca, et al. "Criteria for Cytokine Storm Syndromes." Cytokine Storm Syndrome. Springer, 
Cham, 2019. 61-79. 
2 Ravelli, Angelo, et al. "Macrophage activation syndrome." Hematology/Oncology Clinics 29.5 (2015): 
927-941. 
3 Minoia, Francesca, et al. "Dissecting the heterogeneity of macrophage activation syndrome 
complicating systemic juvenile idiopathic arthritis." The Journal of rheumatology 42.6 (2015): 994-1001. 
He maintained, among other things, that unanticipated 
disasters are never the result or, say, the effect of a 
single motive, of a one and only cause, but resemble a 
vortex, a point of cyclonic depression in the world's 
consciousness: a spot towards which a multiplicity of 
conspiring factors have converged. 
Carlo Emilio Gadda. Quer pasticciaccio brutto de via Merulana. 
Garzanti, 1970 
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severity of the condition, factors responsible of the poor outcome observed among a subgroup 
of MAS patients have not been extensively investigated. In fact, the majority of prognostic studies 
on the HLH/MAS spectrum concentrates on the more severe familiar HLH forms, while few 
evidences on the prognosis of sJIA-related MAS are avaible. Yet, the possibility to predict the 
clinical course at disease diagnosis could have obvious implications for the prompt initiation of 
more aggressive treatments and strict monitoring of high-risk patients. 
While recent advances have been made on the identification of molecular and cytokine-related 
biomarker for the diagnosis and monitoring of disease activity4, most of these tests are not easily 
obtained in clinical practice and not avaible in most centers. 
In this project, we aimed to develop a prognostic model for sJIA-MAS based on routinely avaible 
laboratory parameters collected at MAS onset. For this task, we conducted a re-analysis of the 
dataset gathered in a multinational, multicenter project coordinated by the PRINTO International 
Centre at Gaslini Institute, in Genoa. The study involved a large number of pediatric 
rheumatologists and haemato-oncologists worldwide, with the original aim to develop a set of 
classification criteria for sJIA-MAS5. To account for the complexity and heterogeneity of MAS 
patients, we proceeded through separate analytical steps that were finally integrated in a 
probabilistic risk model. We focused on the prediction of severe outcome, defined in the original 
study as a composite outcome including mortality and admission in Intensive Care Unit, death 
and the development of central nervous system (CNS) dysfunction.  The objectives and results of 
these works, which are reported in the various chapters of this thesis, are recapitulated below.  
In Chapter 1, a literature review of MAS is presented, covering the recent efforts in diagnostic 
and classification approaches. This work has been accepted for publication in the journal 
 
4 Mizuta, Mao, et al. "Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile 
idiopathic arthritis associated macrophage activation syndrome." Cytokine 119 (2019): 182-187. 
5 Ravelli, Angelo, et al. "2016 Classification criteria for macrophage activation syndrome complicating systemic 
juvenile idiopathic arthritis: a European league against rheumatism/American College of Rheumatology/Paediatric 
Rheumatology International Trials Organisation Collaborative Initiative." Arthritis & Rheumatology 68.3 (2016): 
566-576. 
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“Pediatric Allergy and Immunology” with the titled “Macrophage Activation Syndrome in 
Pediatrics”. 
In Chapter 2, we report an explorative subgroup analysis conducted by the means of Latent Class 
Modelling, a method allowing for the identification of homogenous subsets of patients, based on 
selected predictors avaible at diagnosis, among heterogenous populations. The associations with 
baseline features and outcomes are investigated 
In Chapter 3 we assess the prognostic values of routine laboratory parameters at MAS onset to 
identify the most predictive factors by regression modelling. A theoretic, knowledge-based causal 
model for each outcome, formalized as a direct acyclic graph, is employed to addressing possible 
bias. 
In Chapter 4 we further investigate the effects of specific predictors on outcomes to identify the 
causal determinants of clinical course in MAS. For this aim, we employ a causal inference 
approach which allow to estimate the unbiased impact of each risk factor and to identify the 
aspects that need to be targeted to improve the outcome.   
In Chapter 5 we integrate the previous results in the final prognostic model and related score, 
developed within a probabilistic framework.  By means of Bayesian Network methodology and 
constructs from information theory, we identify the most impacting and informative risk factors, 
and present the implementation of a digital tool which provides personalized predictions and can 
assist physicians in clinical decision-making. 
In Chapter 6 we draw the conclusions from the presented work and outline some possible 
directions of future research.  
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Chapter 1 – Macrophage Activation Syndrome in Pediatrics: Diagnostic 
challenges and tools. A review of the literature 
 
Macrophage Activation Syndrome (MAS) is a potentially life-threatening hyperinflammatory 
condition belonging to the spectrum of hemophagocytic lymphohistiocytosis (HLH) that can 
complicate many immunological and rheumatic disorders. HLH describes a group of histiocytic 
disorders driven by the uncontrolled activation of T cells and macrophages exhibiting 
haemophagocytic activity. The current classification of histiocytic disorders includes MAS among 
the forms of HLH occurring in the context of pre-existing disorders, such as infectious, rheumatic 
and oncological diseases – namely secondary or acquired HLH - as opposed to primary or familiar 
forms in which known genetic defects can be identified.  Among rheumatic disease, the highest 
predisposition to developing MAS is observed in patients with systemic juvenile idiopathic 
arthritis (sJIA), 10–30% of which will develop clinical or subclinical MAS at some point of the 
disease course; less frequently, MAS can also occur in Juvenile Systemic Lupus Erythematosus, 
with a reported prevalence of 0.9 to 4.6 %, Kawasaki Disease and Juvenile Dermatomyositis6. 
 
6 Ravelli, Angelo, et al. "Macrophage activation syndrome." Hematology/Oncology Clinics 29.5 (2015): 927-941. 
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Current pathogenetic views suggest that primary and secondary HLH may represent a spectrum 
in which different mechanisms at multiple levels converge in the self-perpetuating activation of 
T cells and macrophages, sustained by the hyperproduction of IFNγ. In primary HLH, this scenario 
is maintained by the alteration of immunoregulatory feedback mechanisms due to genetic 
defects involving the perforin-mediated cytotoxicity pathway. In MAS, multiple mechanisms can 
contribute to macrophage and T-cells hyperactivation, including infectious triggers, hypomorphic 
genetic mutations, and the specific cytokine milieu characterizing some rheumatologic disorders. 
Specifically, the unbalanced production of biologically active IL-18 seems to play a major role in 
predisposing patients with sJIA, Kawasaki Disease and some autoinflammatory disorders to MAS. 
In all these forms, the common endstage of these different pathways will be the overwhelming 
release of pro-inflammatory mediators such as IL-1, IL-6, TNFa - sometimes described as 
“cytokine storm” - resulting in similar clinical phenotypes7. 
Clinically, MAS is characterized by the abrupt onset of unremitting high fever, pancytopenia, 
hyperferritinemia, liver and coagulation dysfunction, eventually progressing, if untreated, in 
multi-organ failure and possible fatal outcome. Encephalopathy is reported in around one-third 
of cases. Bone marrow hemophagocytosis, while supporting the diagnosis, shows low sensitivity 
(approximately 0.60); thus, its absence does not rule out MAS/HLH1. 
Different clinical pictures - including sepsis, viral disease (most frequently EBV), infection from 
intracellular pathogens (Leishmania spp.) - can both mimic and MAS. In rheumatic patients, the 
substantial overlapping between clinical and laboratory features of MAS and the predisposing 
 
7 Bracaglia, Claudia, Giusi Prencipe, and Fabrizio De Benedetti. "Macrophage activation syndrome: different 
mechanisms leading to a one clinical syndrome." Pediatric Rheumatology 15.1 (2017): 5. 
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condition complicates the early recognition of MAS from flares or infections. Moreover, while 
clinically similar to MAS, genetic forms of HLH may warrant specific recognition as they are 
generally more severe, thus requiring more aggressive therapeutic approaches.    
To address these challenges, in the last years a great effort has been made to develop diagnostic 
tools for identifying MAS in specific rheumatic diseases, focusing mostly on sJIA. Generic 
diagnostic guideline for HLH, such as the HLH-2004 diagnostic criteria, have demonstrated low 
sensitivity for MAS in the context of rheumatic conditions, particularly in sJIA. Therefore, an 
international collaboration was established to develop specific diagnostic criteria for MAS 
complicating sJIA. Basing on both expert consensus and data from over 1000 sJIA patients, of 
which 362 diagnosed with MAS, preliminary diagnostic guidelines aimed at differentiating MAS 
from sJIA flare and systemic infections were proposed in 20058. A multistep expert consensus 
process finally led to the development and validation of the 2016 Classification Criteria; according 
to this new set, the diagnosis of MAS in a febrile patient with known or suspect sJIA requires 
serum ferritin level > 684 ng/ml and at least two among the following criteria: platelet count ≤ 
181 × 109/l, aspartate aminotransferase > 48 units/l, triglyceride concentration > 156 mg/dl, 
fibrinogen ≤ 360 mg/dl9. Although altogether sensitive (0.73) and specific (0.99), these criteria 
may be of limited use for the diagnosis of early or subclinical form of MAS in clinical settings10. In 
these cases, it has been suggested that the temporal dynamics of laboratory biomarkers may be 
 
8 Ravelli, Angelo, et al. "Preliminary diagnostic guidelines for macrophage activation syndrome complicating 
systemic juvenile idiopathic arthritis." The Journal of pediatrics 146.5 (2005): 598-604. 
9 Ravelli, Angelo, et al. "2016 Classification criteria for macrophage activation syndrome complicating systemic 
juvenile idiopathic arthritis: a European league against rheumatism/American College of Rheumatology/Paediatric 
Rheumatology International Trials Organisation Collaborative Initiative." Arthritis & Rheumatology 68.3 (2016): 
566-576. 
10 Shimizu, Masaki, et al. "Validation of classification criteria of macrophage activation syndrome in Japanese 
patients with systemic juvenile idiopathic arthritis." Arthritis care & research 70.9 (2018): 1412-1415. 
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more informative than the achievement of an absolute threshold. Specifically, an expert panel 
within the same collaborative project identified platelet count, ferritin, and AST as the 
parameters whose change over time is more relevant for the diagnosis of sJIA-related MAS11. 
Moreover, as shown in a recent systematic review12, the 2016 criteria may underperform for 
patients who develop MAS under IL-1 blocking treatment, which are less likely to be febrile, or 
those under anti-IL-6 medications, which show tendentially lower ferritin and platelets levels. As 
MAS occurs at the onset of SJIA in about 20% of cases13 and molecular testing is not readily 
available in some clinical contexts, the prompt differentiation from primary HLH is not always 
straightforward. A specific index - the MH score- developed by comparing clinical and laboratory 
features of 362 patients with sJIA-related MAS and 258 patients with primary HLH, has been 
proposed to help physicians to discriminate the two conditions. The score includes age at onset 
≤1.6y, splenomegaly, neutrophil count ≤1.4 x109/liter, platelet count ≤78 x109/liter, fibrinogen 
≤131 mg/dl and hemoglobin ≤8.3 g/dl as most suggestive criteria for primary HLH14. Future 
prospective validation studies are warranted to evaluate the utility of these diagnostic tools in 
various settings. 
In summary, MAS is a severe complication occurring in rheumatic diseases, especially sJIA. Recent 
international efforts have provided several consensus tools for the differentiation of MAS from 
 
11 Ravelli, Angelo, et al. "Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation 
syndrome complicating systemic juvenile idiopathic arthritis." RMD open 2.1 (2016): e000161. 
12 Schulert, Grant S., et al. "Effect of biologic therapy on clinical and laboratory features of macrophage activation 
syndrome associated with systemic juvenile idiopathic arthritis." Arthritis care & research 70.3 (2018): 409-419. 
13 Minoia, Francesca, et al. "Clinical features, treatment, and outcome of macrophage activation syndrome 
complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients." Arthritis & 
Rheumatology 66.11 (2014): 3160-3169. 
14 Minoia, Francesca, et al. "Development and initial validation of the macrophage activation syndrome/primary 
hemophagocytic lymphohistiocytosis score, a diagnostic tool that differentiates primary hemophagocytic 
lymphohistiocytosis from macrophage activation syndrome." The Journal of pediatrics 189 (2017): 72-78. 
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confounding diseases and primary HLH, thus assisting diagnosis and enabling future research. 
Together with novel advances in pathogenesis and therapeutic options, these advances are 
expected to improve the outcome of this condition in the future. 
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Chapter 2 - Exploring patterns of biomarkers and organ involvement in 
sJIA-related MAS: a latent class approach 
 
1. Introduction 
Macrophage activation syndrome (MAS), also known as secondary hemophagocytic 
lymphohistiocytosis (HLH), describes a severe hyperinflammatory condition that can complicate 
various systemic illness (e.g., autoimmune disease, malignancy, infection), particularly systemic 
juvenile idiopathic arthritis (SJIA)15. 
The underlying immunopathological mechanisms, which involve an uncontrolled release of 
immune mediators by macrophages and T cells known as a “cytokine storm”, lead to a wide 
spectrum of clinical and laboratory features including sustained fever, hyperferritinemia, 
pancytopenia, hepatobiliary dysfunction, consumptive coagulopathy resembling disseminated 
 
15 Ravelli, Angelo, et al. "Macrophage activation syndrome." Hematology/Oncology Clinics 29.5 (2015): 927-941. 
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intravascular coagulation, and central nervous system (CNS) involvement. If undertreated, MAS 
can evolve into multi-organ failure and ultimately death. 
Despite the recent advances in translational research, which identified IL-18 and IFNγ as driving 
mediators of the syndrome16, the pathophysiological mechanisms leading to organ dysfunction 
in MAS patients are not fully elucidated. The development and evolution of this condition is 
known to be influenced by many factors, including the activity status of the underlying disease, 
received treatments, infection triggers, and genetic alterations17. As a result, presentation and 
severity differ from patient to patient, and the clinical course of can be hardly predictable, with 
a rapid and sometime fulminant progression in the most severe cases18. However, easily avaible 
predictors able to distinguish subject who will develop severe organ involvements have not been 
identified yet. To improve the outcome prediction and identify high-risk subgroup of patients, 
the heterogeneity of MAS needs to be addressed. To explore comprehensively the characteristic 
of these patients at presentation and detect potential laboratory signature that can identify 
subjects with poor outcomes, we analyzed the largest multinational SJIA-related MAS cohort 
collected so far by means of latent class modelling. This a model-based exploratory analysis 
allows to identify multiple unobserved clusters in complex populations by estimating categorical 
latent variables defining homogeneous subgroups. This approach is widely used in different field 
 
16 Crayne, Courtney B., et al. "The Immunology of Macrophage Activation Syndrome." Frontiers in immunology 10 
(2019). 
17 Bracaglia, Claudia, Giusi Prencipe, and Fabrizio De Benedetti. "Macrophage activation syndrome: different 
mechanisms leading to a one clinical syndrome." Pediatric Rheumatology 15.1 (2017): 5. 
18 Minoia, Francesca, et al. "Criteria for Cytokine Storm Syndromes." Cytokine Storm Syndrome. Springer, Cham, 
2019. 61-79. 
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to characterize and stratify patients into risk groups19. Assessing the predictive value of 
laboratory patters at disease onset on the outcomes may improve the recognition of patients 
who are likely to develop a life-threatening disease and thus identify those who would benefit 
most from escalation of treatment. 
2. Materials and Methods 
2.1 Study population 
A multinational cohort of 362 patients diagnosed with sJIA-MAS was analyzed. Data were 
gathered through a web-based survey and included laboratory parameters collected at MAS 
diagnosis, distal outcomes such as mortality and “severe course”, defined as a composite 
outcome given by the occurrence of death or ICU admission. Demographical features Organ 
involvement develop through the clinical course and administered treatments were detailed for 
each patient.  Detailed characteristics of this cohort have been reported previously20. 
2.2 Statistical Methods 
Latent Class (LCA) modeling is a probabilistic technique that uses mixture modelling to identify 
unobserved, homogeneous subgroups of patients (classes or clusters) in an heterogenous 
population, based on the conditional response probabilities of selected observable predictors21. 
 
19 Campbell, Christina A., et al. "Assessing Intervention Needs of Juvenile Probationers: An Application of Latent 
Profile Analysis to a Risk–Need–Responsivity Assessment Model." Criminal Justice and Behavior 46.1 (2019): 82-
100. 
20 Minoia, Francesca, et al. "Clinical features, treatment, and outcome of macrophage activation syndrome 
complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients." Arthritis & 
Rheumatology 66.11 (2014): 3160-3169. 
21 Muthén, B. (2004). Latent variable analysis. In D. Kaplan (Ed.), The Sage handbook of quantitative methodology 
for the social sciences (pp. 345–368). Thousand Oaks, CA: Sage Publications. 
13 
 
Model fit statistics are used to identify the most appropriate number of latent classes22. Posterior 
probabilities indicating the likelihood of membership into each class are estimated. Once 
identified, the classes can be investigated in relation to their association with other variables (not 
included in the model definition) or distal outcomes.  
In this analysis, data were preprocessed by removing highly correlated variables (< Spearmen’s r 
= 0.5). Hemoglobin, whole blood cells, platelets, ERS, CRP, AST, bilirubin, fibrinogen, d-dimer, 
ferritin, BUN and creatinine values avaible at MAS diagnosis were included as class-defining 
variables in the LCA model. Missing data were imputed using multiple imputation procedures. 
 
22 Berlin, Kristoffer S., Natalie A. Williams, and Gilbert R. Parra. "An introduction to latent variable mixture 
modeling (part 1): Overview and cross-sectional latent class and latent profile analyses." Journal of Pediatric 
Psychology 39.2 (2014): 174-187. 
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Fig. 1 – Correlation analysis for avaible laboratory parameters  
We estimated one- through ten-class solutions using maximum likelihood estimation with robust 
standard errors.  As LCA is an unsupervised clustering tool, classification was conducted without 
any consideration of clinical outcomes. Models with one to ten classes were estimated and 
compared. The best-fitting model was selected based on likelihood-based statistics (Akaike 
information criterion or AIC, Bayesian information criterion or BIC, R2-entropy) and model 
interpretability (i.e., face validity; classes including at least 5 % of cases).  To assess the relation 
15 
 
between the obtained clusters and demographic features, clinical manifestation at the onset and 
outcome, a LCA regression analysis was performed using a three-step approach, which involves 
regressing class membership probabilities on the predictor/outcome variables while adjusting for 
the uncertainty in class assignments (Asparouhov & Muthén, 2014; Bakk et al., 2013; Vermunt, 
2010)23. The analysis was performed using Latent Gold software 5.0 (Statistical Innovations, 
Belmont, MA). Preprocessing was done using R. 
        3. Results 
3.1 Latent-Class Modeling: Identification of Number of Subgroups 
A six-class model emerged as the best fitting solution according to selection criteria described 
above. BIC values improved as model complexity increased from 1 through 6 classes. Table 1 
displays a summary of the likelihood-based statistics for each model. The selected model showed 
an R2-entropy of 0.91, indicating an excellent discrimination between the estimated classes. 
Tin contrast to BIC, AIC and AIC3 were lower in the seven-class model than in the six-class one; 
these last indexes are known to favour more complex models and overestimate the number of 
classes 24. 
 
23 Vermunt JK (2010). Latent class modeling with covariates: Two improved three-step approaches. Political 
analysis, 18, 450–469. 
24 Nylund, Karen L., Tihomir Asparouhov, and Bengt O. Muthén. "Deciding on the number of classes in latent class 
analysis and growth mixture modeling: A Monte Carlo simulation study." Structural equation modeling: A 
multidisciplinary Journal 14.4 (2007): 535-569. 
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To directly compare the two models, we performed a Parametric Bootstrapped Likelihood Ratio 
Test (BLRT) that suggested a significant improvement in fit for the seven-class model. Despite 
these elements supporting a better approximation of the data by this model, considering the 
lower entropy value for the seven-class solution, the small number of subjects in the seventh 
class (n = 18) and the similarity between the fifth and seventh class, the six-class model was 
selected. Tab. 1 summarizes the statistic fix indexes for each estimated model. 
Tab 1 – Statistical indexes for each estimated LCA model, from 1 to 10 classes 
The identified classes differed significantly regarding the extent and combination of whole blood 
cells, platelets, ERS, CRP, AST, bilirubin, fibrinogen, d-dimer, ferritin, BUN and creatinine 
alterations. Hb resulted the least discriminating parameter between classes, showing a p of 0.23 
and an R2 of 0,035; nevertheless, considered the prognostic value of this biomarker suggested 
by previous analysis25 and the improvement in discrimination obtained through its inclusion, the 
Hb parameter was retained in the model (Table 2)  
 
25 Minoia, Francesca, et al. "Dissecting the heterogeneity of macrophage activation syndrome complicating 
systemic juvenile idiopathic arthritis." The Journal of rheumatology 42.6 (2015): 994-1001. 
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Tab. 2 – Wald tests, p-values and R2 for the defining parameters (measured at MAS onset) of the 
latent clusters. 
In the following paragraph we provide a brief description and a proposed sub-phenotype name 
based on the mean laboratory values of each class. Table 3 reports the mean values of laboratory 
parameters for each cluster. 
 
Tab 3 – Means value for parameters included in the LCA model characterizing each cluster. All 
values are converted to the international standard unit system: Hemoglobin, g/dl,  White blood 
cell count, × 109/l Platelet count, × 109/l, ESR, mm/h, CRP, mg/dl, AST, U/l, LDH, U/l, Triglycerides, 
18 
 
mg/dl, Albumin, g/dl, Bilirubin, g/dl, Fibrinogen, mg/dl, Ferritin, ng/ml, D-dimer, ng/ml, BUN, 
mg/dl, Creatinine, mg/dl. 
3.2 Laboratory and Clinical features of Subgroups 
Cluster 1: Hyperferritinemia + thrombocytopenia 
This is the largest subgroup, including 93 patients. These subjects presented with high ferritin at 
onset, with mean values around 20.000 ng/ml, associated with a low PLT count (mean value 
around 130.000/mm3). Inflammatory indexes showed high mean values in this group (ESR 51 
mm/h, CRP 12,1 mg/dl). While transaminases were around four times above the norm, no other 
signs of organ dysfunction characterized this cluster. 
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Fig 2- Cluster 1 
 
 
 
 
 
 
 
Cluster 2: Hyper-inflammation 
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Fig 3- Cluster 2 
This cluster containing 83 patients, was almost exclusively characterized by very high 
inflammatory indexes (ESR, CRP, Fibrinogen), PLT and WBC values, with relatively low ferritin 
values (mean values of around 4000 ng/dl) and a very low probability of alteration of parameters 
measuring organ damage. Among this group, the lowest values of serum aspartate 
aminotransferase (AST) and Creatine were observed (respectively mean values of 95 U/l and 0,4 
mg/dl). These patients tended to be younger and with lower SJIA duration at MAS onset then 
other subjects.   
Cluster 3: Pancytopenia  
21 
 
 
Fig 4- Cluster 3 
This subgroup (n. = 82) presented with hematologic involvement, with the lowest values of WBC 
and PLT, but with few other organ dysfunctions. Moreover, these patients exhibited the lowest 
values of CRP (mean around 5 mg/dl) and ferritin levels similar to cluster 2. Modest hepatic 
involvement (AST around 152 U/l, Bilirubin 0,7 g/dl) was also present in this group.  
Cluster 4: Hepatobiliary dysfunction 
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Fig 5- Cluster 4  
This group (n. = 56) was mainly characterized by significant hepatic and biliary involvement, in 
absence of coagulopathy and renal dysfunction. Mean values of AST were around 700 U/L. These 
patients exhibited the highest likelihood of Jaundice, with a mean Bilirubin value of 3,4 mg/dl. 
Albumin levels were slightly reduced; however, no signs of liver insufficiency were evident in this 
group.  
Cluster 5: Acute Kidney Injury + High LDH, Ferritin, Triglycerides   
Fig 5- Cluster 4  
Fig 5- Cluster 4  
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Fig 6- Cluster 5  
These patients (n.=26) exhibited the highest levels of creatinine and BUN, suggesting acute 
kidney injury. The profile was also characterized by Ferritin and LDH levels among the highest, 
coupled with the highest levels of triglycerides. WBC and CRP also reached the highest levels in 
this group, associated with a relatively high platelet count (around 250.000/mm3). Compared to 
cluster 4, the hepatobiliary dysfunction was milder, with AST mean levels around 250 U/l.   
Cluster 6: Liver Insufficiency + Coagulopathy  
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Fig 7- Cluster 6  
This cluster (n.=22) included patients with evidence of hepatic failure, as revealed by mean values 
of AST around 2800 U/L, mean Bilirubin levels around 5 mg/dl and mean Albumin values of 2,6 
g/dl. The lowest value of ESR and Fibrinogen also indicate severe coagulopathy. The highest levels 
of Ferritin, LDH, D-Dimer were observed in this group. There was also evidence of kidney 
involvement (mean Creatinine value around 1 mg/dl), albeit to a lower extent than cluster 5.  
25 
 
A comparison of the laboratory profiles of the different clusters is provided in Fig. 8   
Fig 8- All clusters 
3.3 Comparison of outcomes and predictor variables between clusters 
We found substantial differences between the clusters regarding demographic features, 
treatment requirement and clinical outcomes. 
Patients in Cluster 2 (OR 0.93, 95%Cl 0.93 - 0.94, p = 0.0025) and Cluster 1 (0.96, 95%Cl 0.95 - 
0.96) were younger at MAS onset, while Cluster 3 members were the eldest (OR 1.06, 95%Cl 1.05 
– 1.07).  (Cluster 6 OR 1.01, 95%Cl 1.00 – 1.01) 
26 
 
SJIA duration at onset was lower for cluster 6 (OR 0.90, 95%Cl 0.89 – 0.91, 0 = 0.0034) and Cluster 
2 (OR 0.92, 95%Cl 0.91 – 0.93), while Cluster 3 members had the longest disease duration (OR 
1.14, 95%Cl 1.12 - 1.15). No association was found between age at SJIA onset and cluster 
membership. 
No significant associations were observed between the clusters and geographic provenience, 
specialty of the referral Unit and gender.  
Subjects in Cluster 5 exhibited the worst clinical outcomes, including a significant higher mortality 
rate (OR 2.03, 95%Cl 2.27 - 1.82, p = 0.029). 
Infact, Cluster 5 showed the highest likehood of severe course (OR 3.61, 95%Cl 3.97 - 3.28; p = 
0.0001). Cluster 6 presented with a OR 1.25, (95%Cl 1.27 - 1.23) Subjects in Cluster 2 had the 
lowest probability of severe course (OR 0.34, 95%Cl 0.449 - 0.055; p = 0.0001).   
Cluster 2 membership was also protective for fatal outcome (OR 0.52, 95%Cl 0.58 - 0.47, p = 
0.029). 
Cluster 5 (OR 2.76, 95%Cl 2.95 - 2.59, p<0.0001) and Cluster 6 (OR 1.05, 95%Cl 1.05 – 1.05) had 
the highest risk of multiple organ failure. Cluster 2 membership resulted as protective of multiple 
organ failure (OR 0.66, 95%Cl 0.68 – 0.64). 
Furthermore, Cluster 5 patients had the highest probability of developing CSN dysfunction (OR 
2.54, 95%Cl 2.68 - 2.41, p <0.001), followed by Cluster 6 (OR 1.41, 95%Cl 1.44 - 1.38).  Cluster 2 
had the lowest probability of CSN involvement (OR 0.55, 95%Cl 0.53 - 0.56). 
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Likewise, the highest rate of hemorrhagic complications occurred in Cluster 5 patients (OR 1.72, 
95%Cl 1.82 - 1.62, p = 0.003), followed by cluster 6 (OR 1.33, 95%Cl 1.37 - 1.29). The lowest 
probability was observed in Cluster 2 (OR 0.63, 95%Cl 0.57 - 0.67) and Cluster 3 (OR 0.79, 95%Cl 
0.77 - 0.80). 
Unsurprisingly, the use of corticosteroids and others immunosuppressors was more frequent for 
clusters 4, 5 and 6 than for clusters 1, 2 and 3. Cluster 5 (OR 1.66, 95%Cl 1.79 – 1.54, p 0.021) and 
Cluster 4 (OR 1.52, 95%Cl 1.62 – 1.43) had the highest probability to be treated with Etoposide. 
Cluster 3 had the lower probability of Etoposide treatment (OR 0.49, 95%Cl 0.45 – 0.55). No 
significant differences were detected regarding the use of cyclosporine, intravenous immune 
globulins, plasmapheresis and biologic agents.  No significant interaction between the six classes 
and treatment assignment in predicting severe course and mortality was detected.  
       4. Discussion 
In this work, LCA identified distinct subgroup with different baseline biomarkers profiles, 
demographic features and clinical outcomes in a large, multinational cohort of sJIA-MAS patients. 
The high number of revealed clusters, together with the heterogeneity of their associations, 
confirm the complexity of this multifaceted condition. Despite the elaborateness of the model, 
the clusters represent recognizable patterns of organ involvement that are known to characterize 
HLH/MAS, showing a good face validity from a clinical point of view. These subgroups seem 
unrelated to the geographic provenance of patients and the specialty of the referral center, 
apparently reflecting biological and clinical differences. Among the defining laboratory 
parameters, Hb levels resulted the less discriminative variable, despite being identified as 
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prognostic markers by other analysis.  We found, instead, that biomarkers expressing 
hepatobiliary dysfunction, namely transaminases and bilirubin, contributed more to cluster 
definition, followed by creatinine, ferritin, and platelet count. In other words, these parameters 
showed the greatest variability among MAS patients. Exploring the prognostic utility of these 
biomarkers in further studies could improve the prediction of outcomes. The emerged picture 
reveals a wide spectrum of severity encompassing/ranging from few laboratory alterations and 
lower probability of organ damage, as in cluster 1, 2 and 3, to severe complications and multiple 
dysfunctions, which occur in smaller subgroup, such as cluster 5 and 6. Most of MAS patients 
seem to show hyperferritinemia in combination with thrombocytopenia (cluster 1) or elevated 
inflammatory indexes (cluster 2). Cluster 2, in particular, showed a markedly lower risk of CSN, 
hemorrhagic, hepatic, renal complications, ICU admission and mortality. Infact, this profile 
differed from a typical, uncomplicated SJIA presentation only regarding the level of ferritin (mean 
values around 4600 ng/ml). These patients were younger and were among those with lower sJIA 
duration at MAS onset. This finding agrees is in line with a previous multivariate analysis of the 
same dataset, which identified an older age at MAS onset as a negative prognostic factor. We 
argue that this result in the original analysis was driven by the presence of this young, low-risk 
subgroup, rather than a causal impact of an older age on the clinical outcomes. Moreover, 
disease duration was also relatively lower for patients in the high-risk Cluster 6. Therefore, the 
association between low sJIA duration and could simply reflect difficulties differential diagnosis 
between an active, uncomplicated sJIA at the onset and MAS. Similar to cluster 2, the group 
defined by isolated hematologic alterations, namely cluster 3, had low probability of developing 
organ involvement. These subjects were older and developed MAS after a longer disease 
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duration compared to other clusters. Among the clusters with high incidence of complications, 
cluster 4, which was characterized by hepatobiliary dysfunction but lower probability of 
coagulopathy and renal dysfunction, showed the mildest course. A minority of patients were 
classified in the 2 groups with the most severe presentation. The worst outcome was associated 
with Cluster 5; these patients already presented at onset with acute kidney injury, coagulopathy 
with high D-Dimer levels despite milder hepatic involvement, high LDH and inflammatory 
indexes. This profile was associated with the highest rate of CSN involvement, hemorrhagic 
complications, multiple organ failure, severe course and death. Understandably, these patients 
received more aggressive treatments, including etoposide. The combination of marked LDH and 
D-dimer alteration with high creatinine levels in this group could suggest the occurrence of a 
well-recognized complication of HLH/MAS, namely thrombotic thrombocytopenic purpura (TTP). 
The elevation of Bilirubin despite the relatively mild hepatitis could also reflect a hemolytic 
process, although Hb levels were not significantly lower in this cluster (mean values of 10,5 g/dl). 
However, unlike in classical thrombotic microangiopathy presentations, this profile was not 
associated with significant thrombocytopenia. Rather, this pattern resembles a form of severe 
DIC-like coagulative dysfunction leading to acute kidney injury (AKA). The other high-risk 
subgroup, Cluster 6, showed a full-blown MAS presentation with severe pancytopenia, 
hepatobiliary dysfunction up to liver failure, coagulopathy and renal involvement, albeit in 
absence of AKA. This group showed a slightly lower probability of adverse outcomes (CNS, 
Hemorrhagic, MOF, severe course, death) than to cluster 5; however, direct paired comparison 
between the two clusters failed to demonstrate a significant difference, except for the 
occurrence multiple organ failure (p = 0.02). Interestingly, these patients had also lower disease 
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duration at MAS onset, suggesting that some sJIA patients are actually at risk of severe MAS early 
in their clinical course. Apart from disease duration, we couldn’t find any baseline clinical or 
demographic factor able to discriminate the two high-risk subgroups from other MAS patients. 
Overall, these clusters recapitulate the full spectrum of known MAS manifestations and could 
represent different stages of the pathophysiological process leading from hyperinflammation to 
single organ damage to multiple organ failure.  The current understanding of sJIA-MAS 
pathogenesis, supported by accumulating evidence in animal and human studies, suggests a 
causal role for a cytokine feedback loop involving IL-18 and IFNγ. Serum IL-18 concentrations are 
elevated in a subgroup of patients with SJIA and adult-onset Still’s disease26, and their increment 
precede and correlate with ferritin, transaminase and CRP levels27. Moreover, high IL-18 levels 
predispose patients with SJIA - and several other autoinflammatory conditions28 - to develop MAS 
29. The mechanism underlying this process seems to involve the specific activation of the IFNγ 
pathway in T cells and macrophages by excessive Il-18 signaling30.  The pivotal role of IFNγ in 
HLH/MAS has been demonstrated in several neutralization and clinical studies, which showed a 
strict correlation between levels of IFNγ -induced chemokines in tissues and organ damage31.  In 
 
26 Colafrancesco, Serena, et al. "IL-18 serum level in adult onset Still’s disease: a marker of disease 
activity." International journal of inflammation 2012 (2012). 
27 Shimizu, Masaki, et al. "Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated 
macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis." 
Rheumatology 49.9 (2010): 1645-1653. 
28 Canna SW, de Jesus AA, Gouni S, et al. An activating NLRC4 inflammasome mutation causes autoinflammation 
with recurrent macrophage activation syndrome. Nat Genet. 2014;46:1140–6 
29 Shimizu M, Nakagishi Y, Inoue N, Mizuta M, Ko G, Saikawa Y, et al. Interleukin-18 for predicting the development 
of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Clin Immunol. 2015;160(2):277–81 
30 Girard-Guyonvarc’h, C., Palomo, J., Martin, P., Rodriguez, E., Troccaz, S., Palmer, G., & Gabay, C. (2018). 
Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice. Blood, 131(13), 
1430-1441. 
31 Bracaglia, C., de Graaf, K., Marafon, D. P., Guilhot, F., Ferlin, W., Prencipe, G., ... & Grom, A. A. (2017). Elevated 
circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage 
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this view, the dysregulation of the IL-18-IFNγ feedback underlies a continuum of clinical and 
laboratory manifestations that encompasses both sJIA and MAS as two extremes of a spectrum, 
rather than as two distinct diseases32. Different phases of this immunopathogenic dynamics can 
produce distinct phenotypes, including the occurrence of typical MAS biomarker and pathological 
abnormalities in absence of clinical complications, sometimes referred at as “occult MAS”33. 
Murine models of secondary HLH34 35 support the notion that the IL-18 induced production of 
IFNγ begins at the organ level, i.e. in liver and bone marrow tissues, where it drives inflammation 
and tissue damage; as already proposed for other systemic hyperinflammatory conditions36, 
when the extent or duration of the inflammatory process reaches a certain threshold, the 
response will spill over into other compartments, disseminating systemically and ultimately 
leading to multiple organ failure.  In the light of this pathogenetic model, we argue that the 
identified clusters present with different severity and patterns of organ involvement because of 
different stages of this pathogenetic process. Cluster 2 could represent a subset of patients that 
resides at the sJIA edge of the sJIA-MAS spectrum, and therefore have a low probability to 
develop a full MAS clinical pictures. According to avaible evidences, this profile could be driven 
 
activation syndrome complicating systemic juvenile idiopathic arthritis. Annals of the rheumatic diseases, 76(1), 
166-172. 
32 Bracaglia, C., Prencipe, G., & De Benedetti, F. (2017). Macrophage activation syndrome: different mechanisms 
leading to a one clinical syndrome. Pediatric Rheumatology, 15(1), 5. 
33 Behrens EM, Beukelman T, Paessler M, et al. Occult macrophage activation syndrome in patients with systemic 
Juvenile idiopathic arthritis. J Rheumatol. 2007 May;34(5):1133–1138. PubMed PMID: 17343315 
34 Reinhardt, R. L., Liang, H. E., Bao, K., Price, A. E., Mohrs, M., Ben, L. K., & Locksley, R. M. (2015). A Novel Model 
for IFN-g–Mediated Autoinflammatory Syndromes. 1401992. 
35 Buatois, V., Chatel, L., Cons, L., Lory, S., Richard, F., Guilhot, F., ... & Kosco-Vilbois, M. H. (2017). Use of a mouse 
model to identify a blood biomarker for IFNγ activity in pediatric secondary hemophagocytic lymphohistiocytosis. 
Translational Research, 180, 37-52. 
36 Dick, T. E., Molkov, Y., Nieman, G., Hsieh, Y. H., Jacono, F. J., Doyle, J., ... & Vodovotz, Y. (2012). Linking 
inflammation, cardiorespiratory variability, and neural control in acute inflammation via computational modeling. 
Frontiers in physiology, 3, 222. 
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by elevated serum levels of IL-18 which have not yet determined a widespread induction of the 
IFNγ pathway. Cluster 1, showing some early laboratory alteration such as hyperferritinemia and 
thrombocytopenia, could capture the transition from IL-18 to IFNγ hyperproduction, in other 
words from SJIA to MAS. Cluster 3 and Cluster 4, which are characterized by isolate organ 
involvement, could suggest an hyperproduction of IFNγ that is confined to the organ levels. 
Finally, Cluster 6 and 5 include patients that already present with systemic hyperinflammation 
and severe organ damage at onset.  Although evidences suggest that the transition from one of 
these phases to the others is often non-linear and threshold-wise, these findings highlight the 
importance of a prompt diagnosis and early treatment start for MAS prognosis. Our results must 
be interpreted with caution, considering the many limitations of this study. We analyzed a 
retrospective dataset collected through a web-based survey. Significant percentage of 
missing values were present for many variables, requiring imputation. The original study was 
designed to define a new set of diagnostic criteria for sJIA-MAS, with no original intention to 
investigate prognostic factors.  As a consequence, many important prognostic information, such 
as the time of occurrence of complications and outcomes and duration of treatments, were non 
detailed and unavailable for the analysis. Multiple biomarkers assessments at pre-defined time 
periods were not collected, foreclosing a proper longitudinal analysis. Due to the lack of temporal 
details and the observational nature of the dataset, we couldn’t account for treatment use and 
other post-onset variables when investigating the relationships between clusters and outcomes. 
Moreover, in absence of diagnostic gold standards, study inclusion was based on the diagnostic 
judging of the referral physicians, inherently introducing some degree of subjectivity and 
circularity. Furthermore, the generability of our finding is limited by the fact that the study 
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population included MAS cases diagnosed from 2002 to 2012; consequently, relatively few 
patients were treated with the now more commonly employed biologic therapies such as Anti-
IL6 and Anti-IL1 agents, which recently proved their efficacy in both sJIA and MAS and could 
possibly modify the clinical and laboratory MAS presentation. Finally, due to the small simple size 
of some clusters, we weren’t able to compare the additional  information provided by the latent 
classes with respect to the prognostic value of single laboratory parameters, and assess if the 
improvements is  substantial enough to support the use of this classification as a prognostic tool. 
Further research on external datasets are warranted to investigate the validity and prognostic 
and predictive utility of these subgroups.  Despite these limitations and the inherently explorative 
nature of our analysis, we believe that these findings may add to the understanding of the 
complexity of MAS and provide a proof-of-concept for MAS patient stratification based on 
routine avaible biomarkers. Among the strengths of the study are the analysis of the largest 
multinational MAS cohort collected so far, and the use of a patient-centered analytic 
methodology which, providing a data-drive classification that did not include clinical outcomes 
as class-defining variables, allow to estimate the unbiased associations between subgroups and 
outcomes. 
        5. Conclusions 
In this explorative analysis we identified different subgroups of sJIA-MAS patients with 
distinctives laboratory profiles at disease onset.  The clusters show different clinical and 
demographic features clinical outcomes, and treatment requirement. These findings provide 
insights on the heterogeneity of MAS severity and manifestations and highlight the prognostic 
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values of laboratory patterns at onset. Further analyses are needed to validate these results and 
investigate the potential predictive value of the identified clusters.  
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Chapter 3 – Prognostic values of laboratory markers in sJIA-MAS 
 
1. Introduction 
Macrophage activation syndrome (MAS) is a term describing a constellation of clinical and 
laboratory abnormalities that can occur as a complication of many systemic diseases, with a 
particular frequency in systemic juvenile idiopathic arthritis37, in which occurs in 7–13 % of 
patients.  The disease, now recognized as part of the of hemophagocytic syndromes (HLH), is 
characterized by the uncontrolled release of proinflammatory mediators resulting in a 
widespread systemic inflammation38. The resulting clinical and laboratory picture encompasses 
a wide range of manifestation such as hyperferritinemia, cytopenias, liver dysfunction, and 
coagulopathy resembling disseminated intra-vascular coagulation and neurologic dysfunction. In 
a subgroup of patients, the hyperinflammatory process evolves in organ damage, multiorgan 
failure39 and finally leads to fatal outcome, with reported mortality rates of 22–30 %40. Despite 
the severity of this complication, prognostic factors of MAS have not been fully investigated. In 
the patients with genetic forms of HLH, hyperferritinemia and cerebrospinal fluid (CSF) 
pleocytosis were has been reported to be independent risk factors of adverse outcome41. In 
 
37 Girard-Guyonvarc’h, C., Palomo, J., Martin, P., Rodriguez, E., Troccaz, S., Palmer, G., & Gabay, C. 
(2018). Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in 
mice. Blood, 131(13), 1430-1441. 
38 Buatois, V., Chatel, L., Cons, L., Lory, S., Richard, F., Guilhot, F., ... & Kosco-Vilbois, M. H. (2017). Use of 
a mouse model to identify a blood biomarker for IFNγ activity in pediatric secondary hemophagocytic 
lymphohistiocytosis. Translational Research, 180, 37-52. 
39 Ravelli, Angelo, et al. "Macrophage activation syndrome." Hematology/Oncology Clinics 29.5 (2015): 
927-941. 
40 Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a 
potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001; 
85:421–6 
41 H. Trottestam, E. Berglof, A. Horne, E. Onelov, K. Beutel, K. Lehmberg, E. Sieni, 
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another study, hyperbilirubinemia, hypoalbuminemia, prolonged APTT and elevated LDH 
predicted early mortality; the authors concluded that biomarkers of liver function damage are 
the most useful prognostic factors42. In sJIA-related MAS, however, few evidences on factors 
predicting the development of a complicated course are avaible. The identification of prognostic 
factors could improve MAS outcome allowing for patient stratification and the rational choice of 
appropriate treatments for high-risk subgroups. In this study, we aim to investigate the 
prognostic value of routinely gathered laboratory biomarkers, identifying the most predictive 
parameters for the prediction of unfavorable outcomes, focusing on severe course (as defined as 
the occurrence of of intensive care admission or death) , mortality and the development of CNS 
involvement.  
2. Methods  
2.1 Study population 
The sJIA-MAS cohort analyzed in this study has been already described in previous chapters and 
in dedicated papers43. As our emphasis here is on prediction of outcomes, we included in the 
analysis only laboratory parameters collected at onset and other demographic features, like age, 
that are avaible at MAS diagnosis.  The “severe course” outcome is a composite outcome defined 
as the need of admission to the ICU or a death. CNS disease was defined as the occurrence of 
seizures, lethargy, irritability, headache, mood changes, confusion, coma or other manifestation.  
 
T. Silfverberg, M. Arico, G. Janka, J.I. Henter, Risk factors for early death in children with 
haemophagocytic lymphohistiocytosis, Acta Paediatr. 101 (3) (2012) 
42 Tang, Y., & Luo, Z. (2018). Prognostic factors of early death in children with hemophagocytic 
lymphohistiocytosis. Cytokine, 110, 481-482. doi:10.1016/j.cyto.2017.09.023 
43 Minoia, Francesca, et al. "Dissecting the heterogeneity of macrophage activation syndrome 
complicating systemic juvenile idiopathic arthritis." The Journal of rheumatology 42.6 (2015): 994-1001. 
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As a substantial percentage of observation for some variable was missing (Fig. 1), data were 
imputed by multiple imputation using the R package MICE. 
 
Fig. 1 - Percentage of missing data by variable  
2.2 Data analysis  
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We applied multivariate regression analysis to investigate the relationships between 
predictors and outcomes. To account for the low rate of events for the outcomes of 
interest (35% of the sample developed CNS disease, 27% had a severe course and 8% 
died), we employed Firth’s penalized likelihood in other to reducing small-sample bias in 
regression analysis44. To obtain unbiased estimation of the association between risk 
factors and outcomes, we used Direct Acyclic Graphs (DAGs) to select the set of variables 
to be included in the regression analysis. DAGs are the tools that allow to conceptualize 
the supposed causal relationships between variables according to expert knowledge or 
previous evidences. Visualizing the causal etiological network of involved factors, DAGs 
can be most useful to identify confounders to adjust for in the analysis, in this way 
minimizing bias45.  Once the DAG is designed A mathematical ruleset, known as d-
separation criteria, allows to select the variables to be included in the regression model 
without the risk of over-adjusting46. We thus constructed a DAG of hypothesized causal 
relationships between the factors driving outcomes in sJIA-MAS to identify the initial set 
of variables to be included in the model. The regression model was then implemented 
applying the Allen–Cady Modified Backward Selection procedure. This methodology 
consists in ranking by importance the candidate variables that are not forced into the 
model due to their a priori interest or known confounding role; then, ranked variables are 
deleted through a backward selection, in order of ascending importance. The procedure 
 
44 Heinze, Georg, et al. "Firth's bias reduced logistic regression." R package version 1 (2013). 
45 Williams, Thomas C., et al. "Directed acyclic graphs: a tool for causal studies in paediatrics." Pediatric 
research 84.4 (2018): 487. 
46 Snowden, Jonathan M., et al. "The Curse of the Perinatal Epidemiologist: Inferring Causation Amidst 
Selection." Current epidemiology reports 5.4 (2018): 379-387. 
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is advocated for by experts to limit false-positive results, due to univocally pre-specified 
sequence of model 47. Finally, to detect possible informative cut-offs values useful to 
predict the outcomes, we employed Classification and Regression Trees (CART) analysis  
CARTs are predictive algorithms that perform a binary, recursive splitting of observations 
to obtain subgroups with a similar response48. CARTs can be therefore used identify cut-
off thresholds for the predictors and rank relevant risk factors. Thus, they are a useful for 
constructing decision trees to support decision-making in clinical practice49. CARTs were 
implemented through the R package party. ROC curve then was used to assess the 
accuracy after 10-fold cross-validation. Penalized likehood regression models were 
implemented in STATA 13 (Stata Corporation, College Station, Texas). 
3. Results  
Based on the DAGs, we included in the model demographic features such as age at MAS 
onset, age at sJIA onset and sJIA duration at MAS, as well as laboratory parameters at 
onset. In highly correlated couple of variables (WBC and neutrophilic count, AST and ALT, 
creatinine and BUN) only one of the two parameters was included, based on previous 
knowledge. In the following sections we describe the results for each outcome.  
3.1 Severe course 
 
47 Vittinghoff, Eric, et al. Regression methods in biostatistics: linear, logistic, survival, and repeated 
measures models. Springer Science & Business Media, 2011. 
48 Loh, Wei‐Yin. "Classification and regression tree methods." Wiley StatsRef: Statistics Reference 
Online (2014). 
49 Mburu, Josephine W., et al. "Use of classification and regression tree (CART), to identify hemoglobin 
A1C (HbA1C) cut-off thresholds predictive of poor tuberculosis treatment outcomes and associated risk 
factors." Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 11 (2018): 10-16. 
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Results from the final model for the prediction of severe course are reported in Tab. 1 
Tab. 1-  Coefficients and p-values for the final regression model for severe course 
Creatinine (OR 1.6; 95%Cl 1.13 – 2.3), albumin (OR 0.65; 95%Cl 0.44 – 0.98) and ESR levels (OR 
0.98; 95%Cl 0.98 – 0.99) independent predictors of severe course. CART analysis identified 
creatinine as the only predictive parameter, with 0.9 mg/dl as the cut-offs value distinguishing 
patients at low and high probability of severe outcome (Fig. 2). The prediction accuracy of the 
CART model was 0.6849; 95% CI: (0.5656, 0.7887), the Mcnemar's Test P-Value : 4.49e-06. 
Fig. 2 - CART for severe outcome 
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3.2 Mortality 
As shown in Tab.2, in the final regression model for mortality, serum sodium (OR 0.98; 96%Cl 
0.82-0.96) and creatinine values resulted the main predictors of death risk (OR 1.69; 96%Cl 
1.14-2.5). 
Tab. 2 -  Final regression model for mortality 
 
CART analysis for mortality showed that subject most likely to die were those who 
presented with Na levels < 129 mg/dl and creatinine values > 1,3 mg/dl at onset, as 
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depicted in Fig. 3. The model accuracy was 0.9341, 95% CI : (0.862, 0.9754), with a   
Mcnemar's Test P-Value of 0.0412 
Fig. 3 - CART for mortality 
3.3 CNS disease 
In the regression model for prediction of the development of CNS involvement age at 
MAS onset (OR 0.62; 95%Cl 0.42 – 0.92) and fibrinogen levels (OR 0.99; 95%Cl 0.99 – 0.99) 
were significantly associated with the outcome. Other variables in the model, albeit 
significantly associated, did not confer a substantial risk, as demonstrated by the odd 
ratios. The results are reported in Tab. 3 
 
Tab. 3 - Final regression model for CNS disease 
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Despite this, CART algorithm identified significant cut-offs of ferritin, creatinine and AST levels 
that are predictive of a high risk of CNS dysfunction. The model accuracy was 0.66. (Fig. 4).  
 
Fig. 4 – CART for CNS disease 
4. Discussion 
In this analysis, we identified the main important predictors of unfavorable outcomes and CNS 
dysfunction in sJIA-MAS patients. We took advantage of a causal inference framework for 
estimating unbiased results through the use of Directed Acyclic Graphs. This methodology is 
currently considered the state-of-the art for the analysis of observational data50. In complex 
disease like MAS, where outcome is affected by multiple factors and many analyzed variables 
presumably influences the others, correction of possible confounders is crucial for a correct 
estimation of risk.  DAG-informed regression modelling allowed to identify some predictors of 
outcomes among  variables routinely avaible in clinical practice at MAS onset. Of notice, our 
 
50 Staplin, Natalie, et al. "Use of causal diagrams to inform the design and interpretation of observational 
studies: an example from the Study of Heart and Renal Protection (SHARP)." Clinical Journal of the 
American Society of Nephrology 12.3 (2017): 546-552. 
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results differed from those of a previous analysis of the same cohort, where CNS involvement, 
heart, lung, or kidney failure, hemoglobin ≤ 7.9 g/dl, and age at onset of MAS > 11.5 years were 
independent predictors of severe course. Here, we aimed to predict MAS complications before 
they occurred; therefore, we did not include in the analysis the occurrence of organ failure, as 
the exact timing of occurrence with respect to disease onset was not asked for in the original 
survey. In the current work, nor hemoglobin nor age at MAS onset confirmed their role as 
predictors. This result could be due to the different regression technique, that was chosen to 
minimize small-sample bias, or due the use of DAGs to guide confounders adjustment. In our 
model, hyponatremia and high creatinine levels emerged as strong predictors of mortality, with 
cut-off values compatible with the occurrence of Acute Kidney Injury (AKI). Moreover, creatinine 
levels defined two risk distinct groups according to the CART model, with a threshold value of 0.9 
mg/dl. These results suggest that kidney involvement could play a significant role in the 
occurrence of unfavorable outcomes in MAS. This finding is in line with the results of the latent 
subgroup analysis on the same sample presented in Chapter 2; moreover, it is consistent with 
evidences from the literature on HLH patients. The development of AKI has been reported as a 
risk factor for poor outcome in hemophagocytic syndromes51. Many pathogenetic mechanism 
have been invoked to explain such an involvement. AKI can occur as a consequence of 
hemodynamic dysfunction in the context of multiorgan failure (MOF) that can complicate the 
most severe MAS cases. However, kidney involvement is documented also in patients without 
 
51 Filippone, Edward J., and John L. Farber. "Hemophagocytic lymphohistiocytosis: an update for 
nephrologists." International urology and nephrology 48.8 (2016): 1291-1304. 
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MOF or shock. In most cases, AKI is attributed to acute tubular necrosis52. Thrombotic disease 
could be one of the possible causes of kidney damage. For example, thrombotic microangiopathy 
(TMA) is an increasingly recognized life-threatening condition that can superimpose to MAS, and 
is characterized by hemolytic anemia, decreased platelet counts, high LDH levels and AKI. 
However, also in absence of manifest thrombotic complications, MAS-related coagulopathy 
could play a role, as micro thrombosis of renal vessels has been reported in subject with 
disseminate intravascular coagulopathy (DIC) or DIC-like abnormalities like those seen in MAS53. 
In rare cases, renal injury could be also driven by histiocytic infiltration of the glomerular 
epithelium. Direct cytokinin damage, by TNFa and IL-6, has been proposed in absence of any 
hemodynamic or bioptic alteration54. Further researches are needed to investigate which of 
these mechanisms are more relevant and how kidney involvement should be addressed 
therapeutically in these patients. Regarding the occurrence of CNS dysfunction, 
hypofibrinogenemia resulted a significant risk factor. This suggest that coagulopathy and possibly 
hemorrhagic complication could be important determinants of neurologic complications in MAS.  
Another interesting finding is the inverse association of CNS with age at MAS onset, which 
suggests that younger patients are more susceptible of CNS involvement. Finally, although they 
didn’t emerge as independent predictors for neurologic manifestations, ferritin, creatinine and 
AST values defined high risk-subgroups for CNS complications. In particular ferritin levels above 
 
52 Karras, Alexandre. "What nephrologists need to know about hemophagocytic syndrome." Nature 
Reviews Nephrology 5.6 (2009): 329. 
53 Sakamaki, Yusuke, et al. "Renal thrombotic microangiopathy in a patient with septic disseminated 
intravascular coagulation." BMC nephrology 14.1 (2013): 260. 
54 Wan, L., Bellomo, r., Di Giantomasso, D. & ronco, C. The pathogenesis of septic acute renal 
failure. Curr. Opin. Crit. Care 9, 496–502 (2003). 
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around 8500 ng/ml, creatinine values above 1.3 mg/dl and AST levels above around 550 U/l 
resulted the most predictive thresholds. These finding have to be interpreted with caution, 
considering the many limitations of the study. We analyzed retrospective data gathered though 
a web-based survey, and thus subjected to possible reporting bias and errors. Moreover, the 
effect of treatments on outcomes and possible interactions with laboratory variables were not 
assessed in the analysis. Despite these issues, we believe that the results could encourage further 
prognostic research in MAS and raise the awareness among physicians of the most important 
factors predicting the clinical course in MAS patients.  The implications of the study are twofold; 
in a clinical practice context, the identification of the most predictive risk factors could improve 
patient stratification and assist decision-making promoting the efficacious selection of 
immunosuppressive and supportive treatments.  In research, the classification of patients in risk 
group could help the balancing of study cohorts for a more accurate assessment of efficacy and 
safety questions.  
5. Conclusions 
In this study, we analyzed commonly avaible laboratory markers in sJIA-MAS patients and 
identified the most predictive factors and threshold values for the development of a complicate 
clinical course, CNS disease and mortality in a large multinational cohort.  Further validation, 
possibly in prospective populations, is warranted for the development of adequate prognostic 
models in MAS.  
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Chapter 4 – Understanding causal pathways in SJIA-MAS: a causal 
inference approach to MAS prognosis 
 
1. Introduction 
Macrophage Activation Syndrome (MAS) is a potentially life-threatening hyper-inflammatory 
disorder residing in the group of Hemophagocytic Lymphohistiocytosis (HLH) that can complicate 
several systemic diseases, more frequently Systemic Juvenile Idiopathic Arthritis (SJIA). In some 
cases, MAS rapidly evolves into progressive multi-organ failure and eventually death 55. 
A complex interrelationship of clinical, demographical, etiological and therapeutic factors 
determines in the development, progression, and outcome of this severe condition. 
Despite the recently growing evidence of a key role of specific cytokines – namely IL-18 and INFg 
– in MAS development56, most aspects of the pathogenetic pathways that govern the 
interindividual variation in severity, leading in a subgroup of patients to organ dysfunction and 
systemic widespread of the disease, remain obscure.  
Currently, in the absence of evidence-based guidelines, the rationale for many therapeutic 
options in MAS is based on anecdotic data or inferred by studies on other forms within the HLH 
spectrum57.   
 
55 Ravelli, A., et al. "Macrophage Activation Syndrome." Handbook of Systemic Autoimmune Diseases. Vol. 11. 
Elsevier, 2016. 85-106. 
56 Crayne, Courtney B., et al. "The Immunology of Macrophage Activation Syndrome." Frontiers in immunology 10 
(2019). 
57 Davì, Sergio, et al. "Macrophage Activation Syndrome." Pediatric Rheumatology. Springer, Singapore, 2017. 275-
292. 
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Understanding the causal contribution of different measurable variables to clinical outcomes is 
crucial for risk stratification, rational optimization of treatment sequences and life-saving 
adjuvant interventions, as well as for the development and assessment of novel therapeutic 
interventions. 
Admission laboratory markers can provide useful information to predict the risk of a complicated 
clinical course in SJIA-MAS. However, prediction and causal inference are different concepts. The 
goal of prediction modelling is to develop useful tools to forecast the future occurrence of an 
outcome. Prediction studies do not necessarily include causal factors (targets of intervention), 
but may employ measure surrogates or biomarkers of causes. In the prediction context, causal 
inference is mainly used to incorporate other predictors was necessary to minimize confounding, 
so to obtain an unbiased estimation. Conversely, explanatory studies assess the role of causal 
factors which, if intervened upon through treatment, are likely to modify the outcomes58 59. This 
means that models for causal inference are concerned with optimally deriving the likely change 
in an outcome due to potential change in specific variables, thus informing treatment choices60. 
However, both tasks must be considered in developing a useful prognostic model. As effectively 
pointed out by Gagliardi61, to be adopted as risk factors, predictors must sit in the causal pathway 
of outcomes, so that their manipulation can cause a clinical improvement. Estimating causal 
 
58 Schooling, C. Mary, and Heidi E. Jones. "Clarifying questions about “risk factors”: predictors versus explanation." 
Emerging themes in epidemiology 15.1 (2018): 10. 
59 Arnold, Kellyn F., et al. "DAG-informed regression modelling, agent-based modelling and microsimulation 
modelling: a critical comparison of methods for causal inference." International journal of epidemiology 48.1 
(2018): 243-253. 
60 Arnold, Kellyn F., et al. "Generalised linear models for prognosis and intervention: Theory, practice, and 
implications for machine learning." arXiv preprint arXiv:1906.01461 (2019). 
61 Gagliardi, Luigi. "Prediction and causal inference." Acta Paediatrica 98.12 (2009): 1890-1892. 
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effects from observational data, however, requires special methods, including causal mediation 
analysis and propensity scores62. 
In this study, we aim to explore the causal impact of the identified prognostic factors of outcomes 
in SJIA-MAS, by answering the following question: ‘to what degree do the specific laboratory 
abnormalities increase the risk of developing unfavorable outcomes in MAS patients?’  
For this task, we employed a structural model causal inference approach to unravel the causal 
relationships between demographical, laboratory, clinical and therapeutic variables in a the 
largest multinational SJIA-MAS cohort collected so far. 
2. Methods 
To estimate the causal contributions to the development of severe course, mortality and CNS 
disease, we evaluated the relationships between laboratory predictors at onset and outcomes 
within a structural causal inference framework63. This approach is based on counterfactual 
reasoning, i.e. it compares the potential outcomes between groups who exposed and not 
exposed to factors of interest64.  
Graphical models like directed acyclic graphs (DAGs) are used in this context to formalize the 
hypothesized causal relationships between variables, encoded as conditional independence 
 
62 E. Vittinghoff et al., Regression Methods in Biostatistics, Statistics for Biology 
and Health, DOI 10.1007/978-1-4614-1353-0 1 
63 Pearl J. Causality: Models, Reasoning and Inference. Cambridge, UK: Cambridge University Press; 
2009. 
64 Rubin DB. Estimating causal effects of treatments in randomized and nonrandomized studies. Journal 
of Educational Psychology. 1974; 66(5):688 
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relations in a probability distribution, the truthfulness of which can be assessed empirically in the 
dataset. 
In DAGs, statistical dependencies between variables are represented as arrows between nodes. 
Variables influencing at least two others, including those thought to create or transmit spurious 
associations (confounders) should be added to the model; absence of an arrow between 
(observed or unmeasured) nodes indicates no causal effect65. Once the map of causal 
assumptions is constructed, mathematical rulesets known as d-separation criteria help to 
establish which variables should be controlled for when estimating the effect of one variable on 
another66.  
This formalism also allows distinguishing between the effect of the exposure on outcomes at a 
fixed level of the mediators – the direct effect – and the total effect which includes indirect 
effects via mediating variables67 
We elaborated a separated DAGs of SJIA-MAS for each of the outcomes, accounting for avaible 
laboratory values at onset, clinical and demographic feature, geographic and specialty setting, 
and treatments. The minimal sufficient adjustment sets of variables that would allow the 
identification of an unconfounded effect of specific prognostic factors on outcomes were 
selected. We then queried the DAGs by applying the hill-climbing algorithm to the data and 
 
65 Morgan SL, Winship C, Counterfactuals and Causal Inference: Methods and Principles for Social Research . New 
York: Cambridge University Press, 2007 
66 Ferguson, Karl D., et al. "Evidence synthesis for constructing directed acyclic graphs (ESC-DAGs): a novel and 
systematic method for building directed acyclic graphs." International journal of epidemiology (2019). 
67 Leopold SJ, Watson JA, Jeeyapant A, Simpson JA, Phu NH, Hien TT, et al. (2019) Investigating causal pathways in 
severe falciparum malaria: A pooled retrospective analysis of clinical studies. PLoS Med 16(8): e1002858 
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comparing our theory-driven graphs to the obtained Bayesian network (BN) models, which are 
DAGs learned directly from data. 
Based on emerged condition dependencies encoded in DAGs and BNs and the derived 
adjustment sets, we implemented a multivariable regression model to estimate the unbiased 
effect of candidate predictors on outcomes.  
To evaluate possible non-linear and interdependent effects, we employed multivariate adaptive 
regression splines (MARS)68 and partial dependence plots (PDP)69.  
Finally, to account for possible treatment confounders, marginal posterior probability for the 
treatment effect of cyclosporine and etoposide use on outcomes was estimated through 
augmented inverse probability weighting (AIPW) with double robust methods, which model both 
the outcome and the treatment probability so that only one of the two models must be correctly 
specified to consistently estimate the treatment effects.  
R package MICE was used for data imputation. For DAGs and BNs implementation and we used 
DAGgity and the bnlearn packages through the Causal Analytics Toolkit (CAT) software 
(http://cox-associates.com/CAT.htm). Regression and mediation analyses was performed 
respectively in the MASS and medmod R packages, as implemented by Jamovi software. We used 
 
68 Friedman, Jerome H., and Charles B. Roosen. "An introduction to multivariate adaptive regression splines." 
(1995): 197-217. 
69 Greenwell, Brandon M. "pdp: an R Package for constructing partial dependence plots." The R Journal 9.1 (2017): 
421-436. 
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Stata (version 13.0; StataCorp, LLC) for AIPW70. MARS models were implemented with the Salford 
Predictive Modeler (SPM) 8 software.  
3. Results 
The main goal of this analysis was to estimate unbiased causal effects on the occurrence of severe 
course, CNS disease and fatal outcome in MAS of the  values of Hb (anemia), ferritin, ESR, AST 
(hepatic involvement), creatinine (AKI) at disease onset, as well as of age and SJIA duration at 
MAS diagnosis. 
In the BNs models, we blacklisted71 the arcs from outcomes to baseline laboratory variables and 
from these to the variables of treatments, continent, specialty and demographic features – as we 
assume that the former can’t influence the latter. 
Using d-separation rules and the obtained DAGs, we derived the minimal adjustments that 
allow for unbiased estimates of the causal effects. 
Serum creatinine and Na levels (AKI) emerged as strong predictors of a fatal outcome, as 
described previously. Creatinine levels were the strongest risk factor for a severe course, 
followed by and LDH.  
 
70 Cattaneo, Matias D., David M. Drukker, and Ashley D. Holland. "Estimation of multivalued treatment effects 
under conditional independence." The Stata Journal 13.3 (2013): 407-450. 
71  The term blacklist refers to a set of relationships that, based on previous knowledge, can reasonably be excluded. 
This can regard the association between two variables or the direction of the causal relationship. To avoid the 
incorporation of incorrect links in BN, these relationships are ignored during structure learning. 
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In the following paragraphs the results from the graph models for each outcome, the adjusted 
regression models, as well as the non-linear models and partial dependent plots for the 
evaluation of non-linear relationships are detailed for the predictors of interest.  
3.1 Evaluation of the causal effect of specific predictors on outcomes 
3.1.1 Severe course  
The DAG and estimated hill-climbing algorithm-based BN for severe course are depicted in Fig. 1 
e 2.  
 
Fig. 1 – A priori DAG for severe course 
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Fig. 2 – Bayesian Network for severe course  
Age at sJIA onset  
Age at sJIA onset resulted positively correlated with severe course after adjustment with AST, 
creatinine, d-dimer, disease duration at MAS onset, ferritin, fibrinogen, hemoglobin and platelet 
count, based on Spearman's rank correlation of 0.957 and p-value 0.00. However, the 
relationship resulted not significant in the adjusted regression model (Tab 1) 
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Tab. 1- Regression analysis for the effect of Age at sJIA onset on severe course    
Partial dependence plots (PDPs) reveal an increase of risk for patients with SJIA onset at 2 years 
of age, and again above 12 years of age (Fig 3). 
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Fig. 3 -Partial dependence plots for age at sJIA onset. The plot shows the added-variable plots ( depicting 
the relationship between the response variable and one of the predictors in the regression model, after 
controlling for the presence of the other predictors) for the parameters of interest. 
A similar pattern emerged from the non-linear MARS plot (Fig. 4) 
 
Fig. 4 – MARS model for Age at sJIA onset  
Age at MAS onset 
With an adjustment set of AST, creatinine, d-dimer, disease duration at MAS onset, ferritin, 
fibrinogen, Hb and PLT, Age at MAS onset was positively correlated to the risk of severe course 
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(based on Spearman's rank correlation of 0.988 and p-value 0.000), as shown in PDPs (Fig. 5); 
however, no significant relationship was observed through regression modelling (Tab. 2) 
  
Fig. 5 – PDPs for age at MAS onset  
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Tab. 5 – regression model for age at MAS onset 
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Dispite a similar trend showing an increase of risk above around 7 years of age, MARS model 
confirmed the absence of significant assosiation (Fig 6) 
 
Fig. 6 – MARS model for age at MAS onset 
Disease duration at MAS onset  
Using an adjustment set of age at MAS onset, d-dimer, ESR, ferritin, Hb, LDH, SJIA duration at 
MAS onset appeared positively correlated based on Spearman's test (r 0.986 and p-value 0.000). 
PDPs showing an icrease of risk above around 10 years of disease duration are decipted in Fig. 7. 
However, the association resulted not significant in the regression analysis (p 0.089), as reported 
in Tab. 6. MARS model showed a not significant progressively rising of risk above around 3 years 
of disease duration.     
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Fig. 7 – PDPs for disease duration at MAS onset 
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Tab. 6 – Regression model for disease duration at MAS onset  
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Fig. 8 – MARS model for disease duration at MAS onset 
Hemoglobin 
To assess Hb (anemia) direct effect on the risk of severe course, the DAG suggested a minimal 
adjustment set containing the following variables:  age at MAS onset, disease duration at MAS 
onset, creatinine, d-dimer, ESR, fibrinogen, LDH, PLT.  
No significant association was detected, as shown by the partial dependence plots (Fig 9). Results 
from the logistic model are reported in Table 7.  
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Fig. 9 – PDPs for Hb 
 
95% Confidence 
Interval 
 
Predictor Estimate Lower Upper SE Z p 
Odds 
ratio 
Intercept  0.03825  
-
1.38945 
 1.46595  0.72843  0.0525  0.958  1.039  
Age_at_MAS_onset  
-
0.03144 
 
-
0.09149 
 0.02862  0.03064  
-
1.0260 
 0.305  0.969  
Dis_dur_at_MAS_onset  
-
0.06572 
 
-
0.14839 
 0.01694  0.04218  
-
1.5583 
 0.119  0.936  
Crea_Onset  
-
0.47039 
 
-
0.87668 
 
-
0.06409 
 0.20730  
-
2.2691 
 0.023  0.625  
69 
 
 
95% Confidence 
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95% Confidence 
Interval 
 
Predictor Estimate Lower Upper SE Z p 
Odds 
ratio 
Note. Estimates represent the log odds of "severe course = 0" vs. "severe course = 1" 
Tab. 7 – Regression model fo Hb  
 
MARS model confimed the non-significance of the relationships between Hb and severe 
course, while  showing a non-linear tendency with a progressive descrease of severe course 
risk for Hb values above around 9.5 g/dl (Fig. 10) 
 
 
Fig. 10 – MARS model  for Hb 
Ferritin 
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Adjusting for creatinine and ESR values, a significant direct effect of Ferritin levels on the 
occurrence of a severe course was observed; however, the odd ratio did not actually suggest an 
increased risk depending from ferritin levels (Table 8). 
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Tab. 8 – Regression model for ferritin 
 
72 
 
However, a significantly positive relationship was revealed by Spearman's rank correlation (r 
0.827, p-0.000). PDPs reveal that the risk increases with ferritin levels until it reaches a plateau 
at around 20000 ng/dl, to increase again above levels of around 70000 ng/dl. This pattern was 
confirmed when accounting for the non-linear relationship through MARS regression (Fig 11) 
 
 
Fig. 11 – PDPs and MARS model for Ferritin 
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ESR 
With an adjustment set of age at MAS onset, creatinine, d-dimer, disease duration at MAS onset, 
fibrinogen, LDH and PLT, the direct causal effect of ESR on severe course was not-significant 
(Table 9). PDPs, shown in Fig.12, and MARS regression (not shown) confirmed the absence of a 
significant association.  
  
Fig. 12 – PDPs model for ESR 
Tab. 9 – Below, the regression model for ESR 
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AST 
No adjustment set resulted necessary to estimate the causal effect of hepatic disease (AST 
values) on severe course. As evident by odd ratio intervals, no significant relationship was 
demonstrated.  
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 Tab 10 – regression model for AST 
Albumin 
No adjustment set was required. Results from the regression model are shown in Tab. 11 
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Tab 11 – regression model for albumine 
Fibrinogen 
No adjustment set was required for the direct effect estimation. A significant, inverse 
relatioship between fibrinogen levels and the risk of severe course was detected (Tab.12) 
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95% Confidence 
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Tab 12 – regression model for fibrinogen 
LDH 
The direct effect could be estimated without adjustments. A significant impact of LDH levels on 
severe course was obeserved (Tab.13) 
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95% Confidence 
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Odds 
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Tab 13 – regression model for LDH 
Creatinine 
 
No necessary adjustment set emerged from the DAG. Regression modelling confimed the 
positive relationship with the outcome. MARS model revealed an increase of risk for serum 
creatinine > 0.7 mg/dl (Fig. 12) 
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Tab 13 – regression model for creatinine 
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Fig. 12 – MARS model for creatinine 
The relationship between the distribution of selected parameters the probability of outcome is 
summarized in the plots in Fig.13 
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Fig- 13 - Added Variable Plots show the relationship between the response variable and one of the 
predictors in the regression model, after controlling for the presence of the other predictors 
3.1.2 Death  
The DAG and BN for death are represented in Fig 14. 
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Fig. 14 – A priori and data-drive DAGs for mortality  
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AST 
To assess the effect of hepatic involvement on death risk, according to these DAGs, we selected 
an adjustment set including age at MAS onset, creatinine, d-dimer, fibrinogen, LDH. Despite not 
being an independent predictor of death in the linear regression model (Tab. 14), AST levels 
positively correlated with mortality based on Spearman's test, with r 0.894 and p-value 0.000.  
The non-linear association is illustrated in PDPs, which show a rapid increase in death rate for 
AST values > 4000 U/L. MARS model confirmed the non-linear nature of the association, with an 
increase in death risk above values of around 2500 U/L (Fig. 15)   
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Tab. 14 – regression model for AST  
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Fig. 15 – MARS model and PDPs for AST  
Hemoglobin 
An adjustment set of AST, age at MAS onset, creatinine, d-dimer, fibrinogen, LDH was 
considered. No significant association emerged, as revealed by PDPs (Fig. 16), regression 
modelling (Tab. 15) and MARS (not shown).  
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Fig. 16 – PDPs for Hb  
Model Coefficients 
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Model Coefficients 
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Model Coefficients 
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Tab. 15 – regression model for Hb 
Creatinine 
When adjusted for Na levels, creatinine showed a positive correlation with mortality (Spearman's 
rank correlation 0.781, p-value 0.000). PDPs illustrate the increase in death risk observed for 
creatine levels above around 1.5 mg/dl (Fig. 17). Regression confirmed the relationship between 
creatinine and death risk (Tab. 16) 
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Fig. 17 – PDPs for creatinine  
 
 
95% 
Confidence 
Interval 
 
95% Confidence 
Interval 
Predictor 
Estimat
e 
Lowe
r 
Upper SE Z p 
Odds 
ratio 
Lowe
r 
Upper 
Intercept  12.358  
1.64
7 
 
23.069
1 
 
5.464
8 
 
2.2
6 
 
0.02
4 
 
232880.2
29 
 
5.19
4 
 
1.04e+1
0 
 
Crea_Ons
et 
 0.519  
0.10
6 
 0.9316  
0.210
5 
 
2.4
6 
 
0.01
4 
 1.680  
1.11
2 
 2.539  
90 
 
 
95% 
Confidence 
Interval 
 
95% Confidence 
Interval 
Predictor 
Estimat
e 
Lowe
r 
Upper SE Z p 
Odds 
ratio 
Lowe
r 
Upper 
Na_Onset  -0.113  
-
0.19
4 
 
-
0.0332 
 
0.040
9 
 
-
2.7
7 
 
0.00
6 
 0.893  
0.82
4 
 0.967  
Tab. 16 – PDPs for creatinine  
Sodium 
Adjusting for creatinine, a significant negative relation between serum Na and risk of death was 
confirmed by regression model (already reported above, Tab 16). PDPs show a clear rising in risk 
when Na levels are between 120 and 130 mg/dl (Fig.18).   
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Fig. 18 – PDPs for sodium  
This effect does not depend on a relationship between creatinine and Na (possible due to AKI), 
as confirmed by mediation analysis (Tab 17). 
Na-> Creatinine->Death 
 95% Confidence Interval  
Effect Estimate SE Lower Upper Z p % Mediation 
Indirect  -3.48e−4  8.15e-4  -0.00200  0.00164  -0.427  0.669  3.69  
Direct  -0.00910  0.00508  -0.01946  -3.44e−4  -1.791  0.073  96.31  
Total  -0.00944  0.00526  -0.02023  1.82e-4  -1.796  0.072  100.00  
 Tab. 17 – Mediation analysis for the path Na-> Creatinine->Death 
We also assessed if the effect of hyponatriemia on mortality could be explained by the 
assosiation between death risk and the underlying hyperinflammation (CRP levels) or by 
hemodinamic changes due to multiorgan failure (MOF).  The mediation analyses showed no 
indirect effect in both cases (Tab. 18 and 19).  
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CRP->Na-> Death model 
 95% Confidence Interval  
Effect Estimate SE Lower Upper Z p % Mediation 
Indirect  -7.12e−4  8.51e-4  -0.00261  9.71e-4  -0.837  0.403  7.54  
Direct  -0.00873  0.00489  -0.01841  2.86e-4  -1.785  0.074  92.46  
Total  -0.00944  0.00511  -0.01979  2.23e-4  -1.849  0.064  100.00  
Tab. 18 – Mediation analysis for the path CRP -> Na-> Death 
MOF->Na->Death 
 95% Confidence Interval  
Effect Estimate SE Lower Upper Z p % Mediation 
Indirect  0.00928  0.0129  -0.00586  0.0414  0.719  0.472  5.40  
Direct  0.16252  0.0768  0.00597  0.3188  2.115  0.034  94.60  
Total  0.17180  0.0742  0.02762  0.3299  2.314  0.021  100.00  
Tab. 19– Mediation analysis for the path MOF -> Na-> Death 
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LDH 
The adjustment set included creatinine and sodium. As shown in PDPs (Fig.19), a slight 
significant positive correlation (Spearman's r 0.344, p-value 0.013) emerged between LDH levels 
and mortality, albeit LDH was not an indipendent predictor in the regression model (Tab. 20) 
  
Fig 19– PDPs for LDH 
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Tab. 20– regression model for LDH 
Mediation modelling for the association between serum creatinine values (AKI) and risk of 
Death 
To investigate the possible mechanism underlying the causal pathway linking incremented 
creatinine values (AKI) to mortality, we compared different explanatory models through causal 
mediation analysis.  The conceptual models, based on existing knowledge of potential 
mechanisms of kindey injury in HLH diseases72, are illustrated in Fig.20.  
 
 
 
72 Karras, Alexandre. "What nephrologists need to know about hemophagocytic syndrome." Nature Reviews 
Nephrology 5.6 (2009): 329. 
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Fig.20 – Models of two potential pathofisiological mechanisms driving AKI in MAS, DIC-like coagulopahty 
(disseminated intravascular coagulation) and TMA (thrombotic microangiopahy). Measurable parameters 
useful to empirically test the two models are depicted in black boxes. Modified from Wada, Hideo, et al. 
"Differences and similarities between disseminated intravascular coagulation and thrombotic 
microangiopathy." Thrombosis journal 16.1 (2018): 14. 
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TMA model 
 
Fig.21 –The mediation model formalizing the hypothesis of a TMA-induced kidney injury. 
 
Fig. 21 shows a DAG representing the possible dependencies between laboratory variables based 
on known mechanisms uderlying thrombotic microangiopahy (TMA), a recognized complication 
of MAS73.  To assess if such a mechanism is able to explain the emerged assosiation between AKI 
and death in our cohort, a generalized mediation model was fitted. Results, reported in Tab. 21, 
did not support a pathway involving PLT -> Hb -> Bil. And LDH -> creatinine -> death, suggesting 
that that microangiopathic hemolytic disease is not the main pathogenetic process leading to 
fatal outcomes in our sample.   
 
73 Minoia F, Tibaldi J, Muratore V, et alFRI0565 A MULTINATIONAL STUDY OF THROMBOTIC MICROANGIOPATHY IN 
MACROPHAGE ACTIVATION SYNDROME: A DREADFUL CONDITION WHICH IS LIKELY UNDER-RECOGNIZEDAnnals of 
the Rheumatic Diseases 2019;78:978. 
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Tab. 21 -TMA mediation model 
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Tab. 21 -TMA mediation model 
 95% C.I. (a)  
Type Effect 
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5.34e-
5 
 
0.0204
0 
 
2.026
7 
 0.043  
   
Fib_Onset ⇒ 
Crea_Onset 
⇒ Death 
 1.11e-5  
1.89e-
5 
 
-
2.58e−
5 
 
4.82e-
5 
 
0.0081
2 
 
0.587
3 
 0.557  
   
PLT_Onset 
⇒ Hb_Onset 
⇒ 
Crea_Onset 
⇒ Death 
 9.45e-8  
9.07e-
7 
 
-
1.67e−
6 
 
1.88e-
6 
 
6.92e-
5 
 
0.104
1 
 0.917  
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Tab. 21 -TMA mediation model 
 95% C.I. (a)  
Type Effect 
Estimat
e 
SE Lower Upper β z p 
   
PLT_Onset 
⇒ Bili_Onset 
⇒ 
Crea_Onset 
⇒ Death 
 
-
6.30e−
8 
 
1.13e-
6 
 
-
2.28e−
6 
 
2.14e-
6 
 
-
4.61e−
5 
 
-
0.055
8 
 0.956  
   
PLT_Onset 
⇒ 
LDH_Onset 
⇒ 
Crea_Onset 
⇒ Death 
 
-
3.20e−
6 
 
3.92e-
6 
 
-
1.08e−
5 
 
4.56e-
6 
 
-
0.0023
4 
 
-
0.815
6 
 0.415  
   
Fib_Onset ⇒ 
Hb_Onset ⇒ 
Crea_Onset 
⇒ Death 
 
-
1.39e−
6 
 
2.29e-
6 
 
-
5.85e−
6 
 
3.13e-
6 
 
-
0.0010
2 
 
-
0.608
7 
 0.543  
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Tab. 21 -TMA mediation model 
 95% C.I. (a)  
Type Effect 
Estimat
e 
SE Lower Upper β z p 
   
Fib_Onset ⇒ 
Bili_Onset ⇒ 
Crea_Onset 
⇒ Death 
 3.03e-7  
2.04e-
6 
 
-
3.64e−
6 
 
4.37e-
6 
 
2.22e-
4 
 
0.148
0 
 0.882  
   
Fib_Onset ⇒ 
LDH_Onset 
⇒ 
Crea_Onset 
⇒ Death 
 
-
1.34e−
5 
 
8.66e-
6 
 
-
2.96e−
5 
 
4.34e-
6 
 
-
0.0098
2 
 
-
1.547
7 
 0.122  
Compone
nt 
 
PLT_Onse
t ⇒ 
Hb_Onset 
 
-
8.50e−
5 
 
5.45e-
4 
 
-
0.0011
7 
 
9.70e-
4 
 
-
0.0080
2 
 
-
0.156
0 
 0.876  
   
Hb_Onset 
⇒ Death 
 
-
0.0030
1 
 
0.0075
8 
 
-
0.0170
6 
 
0.0126
7 
 
-
0.0233
9 
 
-
0.397
4 
 0.691  
   
PLT_Onse
t ⇒ 
Bili_Onset 
 3.59e-4  
9.47e-
4 
 
-
0.0015
6 
 
0.0021
5 
 
0.0324
0 
 
0.379
5 
 0.704  
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Tab. 21 -TMA mediation model 
 95% C.I. (a)  
Type Effect 
Estimat
e 
SE Lower Upper β z p 
   
Bili_Onset 
⇒ Death 
 
0.0059
5 
 
0.0084
6 
 
-
0.0106
8 
 
0.0224
9 
 
0.0483
1 
 
0.703
3 
 0.482  
   
PLT_Onse
t ⇒ 
LDH_Ons
et 
 
-
0.8652
0 
 
0.7460
7 
 
-
2.3484
2 
 
0.5761
3 
 
-
0.0503
5 
 
-
1.159
7 
 0.246  
   
LDH_Ons
et ⇒ 
Death 
 
-
7.67e−
6 
 
3.46e-
6 
 
-
1.42e−
5 
 
-
5.99e−
7 
 
-
0.0965
3 
 
-
2.216
9 
 0.027  
   
PLT_Onse
t ⇒ 
Crea_Ons
et 
 
-
2.95e−
4 
 
1.38e-
4 
 
-
5.70e−
4 
 
-
2.97e−
5 
 
-
0.0916
6 
 
-
2.140
0 
 0.032  
   
Crea_Ons
et ⇒ 
Death 
 
0.0730
1 
 
0.0380
5 
 
-
0.0016
5 
 
0.1475
1 
 
0.1719
3 
 
1.918
7 
 0.055  
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Tab. 21 -TMA mediation model 
 95% C.I. (a)  
Type Effect 
Estimat
e 
SE Lower Upper β z p 
   
Fib_Onset 
⇒ 
Hb_Onset 
 
0.0012
5 
 
5.72e-
4 
 
1.38e-
4 
 
0.0023
8 
 
0.1184
1 
 
2.192
6 
 0.028  
   
Fib_Onset 
⇒ 
Bili_Onset 
 
-
0.0017
3 
 
8.95e-
4 
 
-
0.0034
5 
 
5.84e-
5 
 
-
0.1558
7 
 
-
1.928
4 
 0.054  
   
Fib_Onset 
⇒ 
LDH_Ons
et 
 
-
3.6278
7 
 
0.9388
6 
 
-
5.4362
4 
 
-
1.7559
8 
 
-
0.2113
3 
 
-
3.864
1 
 
< .00
1 
 
   
Fib_Onset 
⇒ 
Crea_Ons
et 
 1.52e-4  
2.34e-
4 
 
-
3.05e−
4 
 
6.12e-
4 
 
0.0472
5 
 
0.648
8 
 0.516  
   
Hb_Onset 
⇒ 
Crea_Ons
et 
 
-
0.0152
2 
 
0.0216
2 
 
-
0.0571
8 
 
0.0275
8 
 
-
0.0501
7 
 
-
0.703
9 
 0.482  
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Tab. 21 -TMA mediation model 
 95% C.I. (a)  
Type Effect 
Estimat
e 
SE Lower Upper β z p 
   
Bili_Onset 
⇒ 
Crea_Ons
et 
 
-
0.0024
0 
 
0.0129
3 
 
-
0.0282
7 
 
0.0224
2 
 
-
0.0082
8 
 
-
0.185
7 
 0.853  
   
LDH_Ons
et ⇒ 
Crea_Ons
et 
 5.06e-5  
2.16e-
5 
 
5.86e-
6 
 
9.06e-
5 
 
0.2703
3 
 
2.341
6 
 0.019  
Direct  
PLT_Onset 
⇒ Death 
 
-
5.46e−
5 
 
7.05e-
5 
 
-
1.92e−
4 
 
8.42e-
5 
 
-
0.0399
7 
 
-
0.774
6 
 0.439  
   
Fib_Onset ⇒ 
Death 
 
-
1.43e−
4 
 
8.85e-
5 
 
-
3.19e−
4 
 
2.77e-
5 
 
-
0.1044
6 
 
-
1.610
6 
 0.107  
Total  
PLT_Onset 
⇒ Death 
 
-
7.02e−
5 
 
7.88e-
5 
 
-
2.25e−
4 
 
8.41e-
5 
 
-
0.0514
7 
 
-
0.891
9 
 0.372  
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Tab. 21 -TMA mediation model 
 95% C.I. (a)  
Type Effect 
Estimat
e 
SE Lower Upper β z p 
   
Fib_Onset ⇒ 
Death 
 
-
1.32e−
4 
 
7.87e-
5 
 
-
2.86e−
4 
 
2.21e-
5 
 
-
0.0969
2 
 
-
1.679
5 
 0.093  
 
DIC-like coagulophaty model 
The laboratory relationships assumed in the model supposing a causal role for disseminated 
intravascular-like coagulophaty are decipted in Fig. 22. 
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Fig 22 – DAG for a DIC-mediated kidney injury in SJIA-MAS. Covariance between indipendent variables 
are not shown 
 
As reported in Tab.22, a significant indirect effect links d-dimer values (compsuntive 
coagulopathy) and death risk, through kidney dysfunction (creatinine). As d-dimer has not direct 
effect on mortality, its effect appears totally mediated by kidney injury. While fibrinogen is 
associated with PLT levels; however, indirect effects involving these two parameters are not 
significant.  
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Tab. 22 -DIC-like coagulophaty model 
 95% C.I. (a)  
Type Effect 
Estimat
e 
SE Lower Upper β z p 
Indirect  
Ddi_Onset ⇒ 
Crea_Onset 
⇒ DeathYN 
 
0.0097
8 
 
0.0042
3 
 
0.0014
9 
 
0.0180
7 
 
0.0352
0 
 
2.31
3 
 0.021  
   
Ddi_Onset ⇒ 
PLT_Onset ⇒ 
DeathYN 
 6.70e-4  
0.0012
2 
 
-
0.0017
2 
 
0.0030
6 
 
0.0024
1 
 
0.54
9 
 0.583  
   
Fib_Onset ⇒ 
Crea_Onset 
⇒ DeathYN 
 
-
5.76e−
4 
 
0.0022
3 
 
-
0.0049
4 
 
0.0037
9 
 
-
0.0021
0 
 
-
0.25
9 
 0.796  
   
Fib_Onset ⇒ 
PLT_Onset ⇒ 
DeathYN 
 
-
0.0036
0 
 
0.0060
7 
 
-
0.0155
0 
 
0.0083
1 
 
-
0.0131
4 
 
-
0.59
2 
 0.554  
   
Ddi_Onset ⇒ 
PLT_Onset ⇒ 
Crea_Onset 
⇒ DeathYN 
 2.42e-4  
2.49e-
4 
 
-
2.46e−
4 
 
7.30e-
4 
 
8.69e-
4 
 
0.97
0 
 0.332  
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Tab. 22 -DIC-like coagulophaty model 
 95% C.I. (a)  
Type Effect 
Estimat
e 
SE Lower Upper β z p 
   
Fib_Onset ⇒ 
PLT_Onset ⇒ 
Crea_Onset 
⇒ DeathYN 
 
-
0.0013
0 
 
0.0010
0 
 
-
0.0032
6 
 
6.65e-
4 
 
-
0.0047
4 
 
-
1.29
5 
 0.195  
Compone
nt 
 
Ddi_Onset 
⇒ 
Crea_Ons
et 
 
0.2521
6 
 
0.0536
2 
 
0.1470
6 
 
0.3572
6 
 
0.2434
2 
 
4.70
2 
 
< .00
1 
 
   
Crea_Ons
et ⇒ 
DeathYN 
 
0.0387
9 
 
0.0146
1 
 
0.0101
6 
 
0.0674
1 
 
0.1446
0 
 
2.65
6 
 0.008  
   
Ddi_Onset 
⇒ 
PLT_Onse
t 
 
-
0.0728
1 
 
0.0505
6 
 
-
0.1719
0 
 
0.0262
8 
 
-
0.0708
6 
 
-
1.44
0 
 0.150  
   
PLT_Onse
t ⇒ 
DeathYN 
 
-
0.0092
0 
 
0.0155
0 
 
-
0.0395
7 
 
0.0211
7 
 
-
0.0340
3 
 
-
0.59
4 
 0.553  
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Tab. 22 -DIC-like coagulophaty model 
 95% C.I. (a)  
Type Effect 
Estimat
e 
SE Lower Upper β z p 
   
Fib_Onset 
⇒ 
Crea_Ons
et 
 
-
0.0148
6 
 
0.0571
4 
 
-
0.1268
4 
 
0.0971
3 
 
-
0.0145
6 
 
-
0.26
0 
 0.795  
   
Fib_Onset 
⇒ 
PLT_Onse
t 
 
0.3909
1 
 
0.0498
1 
 
0.2932
8 
 
0.4885
4 
 
0.3861
5 
 
7.84
8 
 
< .00
1 
 
   
PLT_Onse
t ⇒ 
Crea_Ons
et 
 
-
0.0855
4 
 
0.0566
1 
 
-
0.1964
9 
 
0.0254
0 
 
-
0.0848
5 
 
-
1.51
1 
 0.131  
Direct  
Ddi_Onset ⇒ 
DeathYN 
 
0.0074
6 
 
0.0150
9 
 
-
0.0221
1 
 
0.0370
3 
 
0.0268
5 
 
0.49
4 
 0.621  
   
Fib_Onset ⇒ 
DeathYN 
 
-
0.0259
6 
 
0.0155
9 
 
-
0.0565
2 
 
0.0046
0 
 
-
0.0948
2 
 
-
1.66
5 
 0.096  
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Tab. 22 -DIC-like coagulophaty model 
 95% C.I. (a)  
Type Effect 
Estimat
e 
SE Lower Upper β z p 
Total  
Ddi_Onset ⇒ 
DeathYN 
 
0.0181
5 
 
0.0147
7 
 
-
0.0107
9 
 
0.0471
0 
 
0.0653
3 
 
1.22
9 
 0.219  
   
Fib_Onset ⇒ 
DeathYN 
 
-
0.0314
3 
 
0.0145
5 
 
-
0.0599
5 
 
-
0.0029
1 
 
-
0.1148
0 
 
-
2.16
0 
 0.031  
 
Demographic features 
Age at sJIA onset 
With an adjustment set including AST, age at MAS onset, creatinine, ddimer, fibrinogen, and 
LDH, we found not significant association with mortality.  
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Model Coefficients 
 
95% Confidence 
Interval 
 
95% 
Confidence 
Interval 
Predictor 
Estima
te 
Lower Upper SE Z p 
Odd
s 
ratio 
Lowe
r 
Uppe
r 
Intercept  
-
2.2258
8 
 
-
3.3330
5 
 
-
1.1187 
 
0.564
90 
 
-
3.94
0 
 
< .00
1 
 
0.10
8 
 
0.035
7 
 
0.32
7 
 
Fib_Onset  
-
0.0028
1 
 
-
0.0054
5 
 
-
1.75e
−4 
 
0.001
35 
 
-
2.09
0 
 
0.03
7 
 
0.99
7 
 
0.994
6 
 
1.00
0 
 
LDH_Onset  
-
1.58e−
4 
 
-
3.47e
−4 
 
3.08e-
5 
 
9.64e-
5 
 
-
1.64
1 
 
0.10
1 
 
1.00
0 
 
0.999
7 
 
1.00
0 
 
Age_at_MAS_o
nset 
 
0.0492
6 
 
-
0.0547
3 
 0.1532  
0.053
05 
 
0.92
8 
 
0.35
3 
 
1.05
0 
 
0.946
7 
 
1.16
6 
 
AST_Onset  
2.31e-
4 
 
-
7.00e
−5 
 
5.32e-
4 
 
1.53e-
4 
 
1.50
4 
 
0.13
3 
 
1.00
0 
 
0.999
9 
 
1.00
1 
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Model Coefficients 
 
95% Confidence 
Interval 
 
95% 
Confidence 
Interval 
Predictor 
Estima
te 
Lower Upper SE Z p 
Odd
s 
ratio 
Lowe
r 
Uppe
r 
Ddi_Onset  
2.62e-
5 
 
-
3.06e
−5 
 
8.30e-
5 
 
2.90e-
5 
 
0.90
4 
 
0.36
6 
 
1.00
0 
 
1.000
0 
 
1.00
0 
 
Crea_Onset  
0.6347
1 
 
0.1723
4 
 1.0971  
0.235
91 
 
2.69
1 
 
0.00
7 
 
1.88
6 
 
1.188
1 
 
2.99
5 
 
Age_at_onset  
-
0.0504
8 
 
-
0.1737
0 
 0.0727  
0.062
87 
 
-
0.80
3 
 
0.42
2 
 
0.95
1 
 
0.840
5 
 
1.07
5 
 
Tab. 23 – regression for Age at SJIA onset 
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Fig. 23 – PDPs  for Age at SJIA onset 
Age at MAS onset 
With an adjustment set including creatinine, ddimer, fibrinogen, Hb, LDH and sodium values, no 
significant relationship with mortality emerged from linear and MARS models, despite an 
apparent positive correlation, illustrated in PDPs (Spearman's rank correlation of 0.949, p-value 
0.000).  
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Tab. 24 – regression model for age at MAS onset 
 
95% 
Confidence 
Interval 
 
95% 
Confidence 
Interval 
Predictor 
Estima
te 
Lower Upper SE Z p 
Odds 
ratio 
Low
er 
Upper 
Intercept  
10.629
74 
 
-
0.371
26 
 
21.63
07 
 
5.612
86 
 
1.89
38 
 
0.05
8 
 
41346.2
08 
 
0.69
0 
 
2.48e
+9 
 
Fib_Onset  
-
0.0027
2 
 
-
0.005
31 
 
-
1.24e
−4 
 
0.001
32 
 
-
2.05
33 
 
0.04
0 
 0.997  
0.99
5 
 1.000  
LDH_Onset  
-
1.25e−
4 
 
-
3.02e
−4 
 
5.29e-
5 
 
9.06e
-5 
 
-
1.37
66 
 
0.16
9 
 1.000  
1.00
0 
 1.000  
Age_at_MAS_
onset 
 
0.0607
4 
 
-
0.049
35 
 
0.170
8 
 
0.056
17 
 
1.08
14 
 
0.28
0 
 1.063  
0.95
2 
 1.186  
Ddi_Onset  
2.33e-
5 
 
-
3.27e
−5 
 
7.93e-
5 
 
2.86e
-5 
 
0.81
46 
 
0.41
5 
 1.000  
1.00
0 
 1.000  
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Tab. 24 – regression model for age at MAS onset 
 
95% 
Confidence 
Interval 
 
95% 
Confidence 
Interval 
Predictor 
Estima
te 
Lower Upper SE Z p 
Odds 
ratio 
Low
er 
Upper 
Crea_Onset  
0.5734
7 
 
0.090
61 
 
1.056
3 
 
0.246
36 
 
2.32
78 
 
0.02
0 
 1.774  
1.09
5 
 2.876  
Age_at_onset  
-
0.0521
5 
 
-
0.174
52 
 
0.070
2 
 
0.062
44 
 
-
0.83
52 
 
0.40
4 
 0.949  
0.84
0 
 1.073  
Hb_Onset  
-
0.0094
0 
 
-
0.209
42 
 
0.190
6 
 
0.102
05 
 
-
0.09
21 
 
0.92
7 
 0.991  
0.81
1 
 1.210  
Na_Onset  
-
0.0951
2 
 
-
0.179
01 
 
-
0.011
2 
 
0.042
80 
 
-
2.22
25 
 
0.02
6 
 0.909  
0.83
6 
 0.989  
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Fig. 24 – PDPs  for Age at MAS onset 
Added-variable plots for death and selected parameters are shown below (Fig. 25) 
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Fig.25 – Added-variable plots summarizing the  relatioship between death and selected parameters 
3.1.3 CNS disease 
The DAG and BN for CNS disease are reported below (Fig. 26) 
 
Fig.26 – A priori and data-driven DAGs for CNS disease 
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Age at MAS onset 
When adjusting for LDH and creatinine, a negative correlation between age at MAS onset and 
CNS was observed, based on Spearman's rank correlation of -0.685, p-value 0.000 (PDPs shown 
in Fig.27). However, logistic regression did not show a significant association (Tab. 25) 
  
Fig.27 – PDPs for age at MAS onset 
 
95% 
Confidence 
Interval 
 
95% 
Confidence 
Interval 
Predictor 
Estimat
e 
Lower Upper SE Z p 
Odds 
ratio 
Lowe
r 
Uppe
r 
Intercept  
-
1.2228 
 
-
1.736
3 
 
-
0.709
3 
 
0.262
0 
 
-
4.66
8 
 
< .00
1 
 
0.29
4 
 
0.17
6 
 
0.49
2 
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95% 
Confidence 
Interval 
 
95% 
Confidence 
Interval 
Predictor 
Estimat
e 
Lower Upper SE Z p 
Odds 
ratio 
Lowe
r 
Uppe
r 
Age_at_MAS_on
set 
 
-
0.0163 
 
-
0.061
7 
 
0.029
1 
 
0.023
1 
 
-
0.70
4 
 0.482  
0.98
4 
 
0.94
0 
 
1.02
9 
 
LDH_Onset  
8.97e-
5 
 
3.83e
-6 
 
1.76e
-4 
 
4.38e
-5 
 
2.04
7 
 0.041  
1.00
0 
 
1.00
0 
 
1.00
0 
 
Crea_Onset  0.8032  
0.306
9 
 
1.299
4 
 
0.253
2 
 
3.17
2 
 0.002  
2.23
3 
 
1.35
9 
 
3.66
7 
 
Note. Estimates represent the log odds of "CNS = 1" vs. "CNS = 0" 
 Tab. 25 – regression model for age at MAS onset 
Age at sJIA onset 
Adjusting for age at MAS onset, there was a negative correlation (Spearman's r -0.447, p-value 
0.001) between age at sJIA onset and CNS dysfunction (PDPs in Fig. 28). No significant relationship 
was detected by regression modelling (Tab. 26).  
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Fig.28 – PDPs for age at sJIA onset 
 
95% 
Confidence 
Interval 
 
95% 
Confidence 
Interval 
Predictor 
Estimat
e 
Lower Upper SE Z p 
Odds 
ratio 
Lowe
r 
Uppe
r 
Intercept  
-
0.6311
5 
 
-
1.054
2 
 
-
0.208
1 
 
0.215
8 
 
-
2.924
2 
 
0.00
3 
 
0.53
2 
 
0.34
8 
 
0.81
2 
 
Age_at_MAS_on
set 
 
0.0032
3 
 
-
0.064
5 
 
0.070
9 
 
0.034
5 
 
0.093
4 
 
0.92
6 
 
1.00
3 
 
0.93
8 
 
1.07
3 
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95% 
Confidence 
Interval 
 
95% 
Confidence 
Interval 
Predictor 
Estimat
e 
Lower Upper SE Z p 
Odds 
ratio 
Lowe
r 
Uppe
r 
Age_at_onset  
-
0.0026
1 
 
-
0.078
9 
 
0.073
7 
 
0.038
9 
 
-
0.066
9 
 
0.94
7 
 
0.99
7 
 
0.92
4 
 
1.07
7 
 
 Tab. 25 – regression model for age at sJIA onset 
Disease duration  
Despite the PDPs show a significantly negative (based on Spearman's rank correlation of -0.923 
and p-value 0.000) after adjustment for age at MAS onset, no evidence of association was 
found with the regression model (Tab 26) 
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Fig.29 – PDPs for age disease duration 
 
 
95% 
Confidence 
Interval 
 
95% 
Confidence 
Interval 
Predictor 
Estimat
e 
Lower 
Uppe
r 
SE Z p 
Odd
s 
ratio 
Lowe
r 
Uppe
r 
Intercept  
-
0.6233
7 
 
-
1.045
1 
 
-
0.201
6 
 
0.215
2 
 
-
2.89
7 
 
0.00
4 
 
0.53
6 
 
0.35
2 
 
0.81
7 
 
Age_at_MAS_onset  
-
0.0035
8 
 
-
0.051
6 
 
0.044
4 
 
0.024
5 
 
-
0.14
6 
 
0.88
4 
 
0.99
6 
 
0.95
0 
 
1.04
5 
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Fig.29 – PDPs for age disease duration 
 
 
95% 
Confidence 
Interval 
 
95% 
Confidence 
Interval 
Predictor 
Estimat
e 
Lower 
Uppe
r 
SE Z p 
Odd
s 
ratio 
Lowe
r 
Uppe
r 
Dis_dur_at_MAS_o
nset 
 
0.0165
2 
 
-
0.057
6 
 
0.090
6 
 
0.037
8 
 
0.43
7 
 
0.66
2 
 
1.01
7 
 
0.94
4 
 
1.09
5 
 
 Tab. 26 – regression model for disease duration  
Fibrinogen 
123 
 
No adjustment set was required to assess the direct effect of fibrinogen levels (coagulopathy) on 
CNS disease. A significant association was confirmed by logistic regression (Tab. 27), with higher 
values being protective for CNS involvement development. We further assessed if this 
relationship depends on the occurrence of clinical hemorrhagic manifestations, through a 
mediation analysis.  As shown in Table 27 and Fig.30, we found that the impact of fibrinogen is 
only partially (25% of the effect) explained by hemorrhagic complications. 
Model Coefficients 
 
95% Confidence 
Interval 
 
95% 
Confidence 
Interval 
Predict
or 
Estimate Lower 
Uppe
r 
SE Z p 
Odds 
ratio 
Lower 
Up
pe
r 
Inter
cept 
 
0.066
21 
 
-
0.35
210 
 
0.4
845
3 
 
0.21
3 
 0.310  0.756  1.068  
0.70
3 
 
1.
62
3 
 
Fib_
Onse
t 
 
-
0.002
31 
 
-
0.00
357 
 
-
0.0
010
6 
 
6.40
e-4 
 
-
3.611 
 < .001  0.998  
0.99
6 
 
0.
99
9 
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Model Coefficients 
 
95% Confidence 
Interval 
 
95% 
Confidence 
Interval 
Predict
or 
Estimate Lower 
Uppe
r 
SE Z p 
Odds 
ratio 
Lower 
Up
pe
r 
Mediation Estimates 
 
95% Confidence 
Interval 
 
Effec
t 
Estimat
e 
SE Lower Upper Z p 
% 
Mediation 
Ind
irec
t 
 
-
1.14e
−4 
 
4.27
e-5 
 
-
2.13e−4 
 
-
4.52e−
5 
 -2.67  0.008  25.3  
Dir
ect 
 
-
3.37e
−4 
 
1.37
e-4 
 
-
6.01e−4 
 
-
6.10e−
5 
 -2.46  0.014  74.7  
Tot
al 
 
-
4.51e
−4 
 
1.38
e-4 
 
-
7.25e−4 
 
-
1.73e−
4 
 -3.27  0.001  100.0  
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Path Estimates 
 
95% Confidence 
Interval 
 
      Estimate SE Lower Upper Z p 
Fib_Onset  →  Hemorrhagic  
-
3.73e−4 
 
1.01e-
4 
 
-
5.79e−4 
 
-
1.81e−4 
 
-
3.68 
 < .001  
Hemorrhagic  →  CNS  0.305  0.0660  0.170  0.436  4.63  < .001  
Fib_Onset  →  CNS  
-
3.37e−4 
 
1.37e-
4 
 
-
6.01e−4 
 
-
6.10e−5 
 
-
2.46 
 0.014  
 
 Tab. 27 – regression model for fibrinogen and mediation model for the path fibrinogen-> hemorragic 
manifestations-> CNS disease  
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Fig.30 – Direct and indirect effects in the mediation model for the path fibrinogen-> hemorragic 
manifestations-> CNS disease  
Ferritin 
No adjustment was need according to the DAG. Ferritin levels were significantly associated with 
CNS disease occurrence (OR 1.69, 95%Cl 1.33 – 2.1). A significant interaction effect emerged 
between ferritin and age at MAS onset, such as for specific ferritin values the risk of CNS 
involvement is higher at younger age, as shown in Tab. 28 and Fig. 31. 
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95% Confidence 
Interval 
 
95% Confidence 
Interval 
Predictor Estimate Lower Upper SE Z p 
Odds 
ratio 
Lower Upper 
Intercept  -0.636  -0.864  -0.409  0.116  
-
5.48 
 < .001  0.529  0.422  0.664  
Ferr_Onset  0.530  0.291  0.769  0.122  4.34  < .001  1.699  1.338  2.158  
Note. Estimates represent the log odds of "CNS = 1" vs. "CNS = 0" 
  
 95% Confidence Interval  
  Estimate SE Lower Upper Z p 
Ferr_Onset  0.13202  
0.0249
6 
 
0.083
1 
 
0.180
95 
 
5.2
89 
 
< .00
1 
 
Age_at_MAS_
onset 
 -0.00192  
0.0047
2 
 
-
0.011
2 
 
0.007
33 
 
-
0.4
06 
 0.684  
Ferr_Onset ✻ 
Age_at_MAS_
onset 
 -0.01033  
0.0051
2 
 
-
0.020
4 
 
-
2.96e
−4 
 
-
2.0
18 
 0.044  
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 95% Confidence Interval  
  Estimate SE Lower Upper Z p 
 95% Confidence Interval  
  Estimate SE Lower Upper Z p 
Average  
0.132
8 
 0.0252  
0.083
4 
 
0.18
2 
 5.27  
< .00
1 
 
Low (-
1SD) 
 
0.186
5 
 0.0408  
0.106
6 
 
0.26
6 
 4.58  
< .00
1 
 
High 
(+1SD) 
 
0.079
1 
 0.0322  
0.016
1 
 
0.14
2 
 2.46  0.014  
 Tab. 28 – Moderation model forthe effect of ferritin levels on CNS disease. The table shows the effect 
of the predictor (ferritin) on the dependent variable (CNS) at different levels of the moderator (age at 
MAS onset) 
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Fig.31 – The plot illustrates the relatioship netween ferritin values and risk of CNS disease according to 
different values of age at MAS onset (colored slopes) 
Creatinine 
In absence of a required adjustment set, the estimated directed effect of creatinine levels (AKI) 
on CNS disease occurrence was significant (Tab.29). Mediation analysis showed that this 
association is partly (around 20%) due to the association of AKI with heart failure (Tab 31 and Fig. 
32). 
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Model Coefficients 
 
95% Confidence 
Interval 
 
95% Confidence 
Interval 
Predictor Estimate Lower Upper SE Z p 
Odds 
ratio 
Lower Upper 
Intercept  -1.223  -1.610  -0.837  0.197  
-
6.20 
 < .001  0.294  0.200  0.433  
Crea_Onset  0.889  0.410  1.369  0.245  3.63  < .001  2.434  1.506  3.932  
 Tab. 29 – Regression model of creatinine for CNS disease 
Mediation Estimates 
 95% Confidence Interval  
Effect Estimate SE Lower Upper Z p % Mediation 
Indirect  0.0319  0.0153  0.00139  0.0645  2.08  0.037  17.6  
Direct  0.1492  0.0435  0.07023  0.2408  3.43  < .001  82.4  
Total  0.1811  0.0386  0.10498  0.2606  4.69  < .001  100.0  
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Path Estimates 
 95% Confidence Interval  
      Estimate SE Lower Upper Z p 
Crea_Onset  →  heartfail  0.0753  0.0341  0.0101  0.141  2.21  0.027  
heartfail  →  CNS  0.4234  0.1287  0.1141  0.627  3.29  0.001  
Crea_Onset  →  CNS  0.1492  0.0435  0.0702  0.241  3.43  < .001  
Tab. 31 – Mediation model for the path cratinine-> heart failure-> CNS 
 
Fig. 32 –Direct and indirect effects in r the path cratinine-> heart failure-> CNS 
 
Added-variable plots highlight the relationship between the risk of  CNS disease and the 
examined variables (Fig. 33) 
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Fig. 33 – Added-variable plots for selected predictors 
3.2 Accounting for treatment effect on outcomes: estimation of causal impact of 
Cyclosporine and Etoposide therapy through Inverse Probability Weighting (IPW) 
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Immunosuppressive treatments have a major impact on outcomes. Ignoring treatment effects in 
prognostic models limits the accuracy and generability of results74. We therefore investigated the 
causal effect of these treatments on severe course and mortality. In this cohort, the 97,7% of 
patients were given corticosteroids, precluding any comparison between treated and not-treated 
subjects. Cyclosporine was used in 61.2 %, while Etoposide in 40%. These treatments were 
plausibly administered in most severe cases75, with difference according to the geographic and 
specialty settings. To accounting for this unbalance in treatment effect estimations, we employed 
augmented IPW with double robust methods 76. The adjustment sets were based on the DAGs 
for severe course and death, shown in Fig 34. We found no evidence for a significant effect of 
cyclosporine or etoposide on severe course and death rate. Tab. 32 shows the Potential-outcome 
means (POMs) and Average Treatment Effect for the Treated (ATET) coefficients, p-values and 
odd ratios for both treatments.  Tab. 33 shows the standardized differences between the 
etoposide treated and not-treated groups before and after IPW for all the included parameters. 
 
74 Pajouheshnia, R., Damen, J.A.A.G., Groenwold, R.H.H. et al. Treatment use in prognostic model research: a 
systematic review of cardiovascular prognostic studies. Diagn Progn Res 1, 15 (2017) doi:10.1186/s41512-017-
0015-0 
75 Minoia, Francesca, et al. "Dissecting the heterogeneity of macrophage activation syndrome complicating 
systemic juvenile idiopathic arthritis." The Journal of rheumatology 42.6 (2015): 994-1001. 
76 Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting 
(IPTW) using the propensity score to estimate causal treatment effects in observational studies. Statistics in 
Medicine. 2015; 34(28):3661–3679. 
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Fig. 34 – DAGs for the death and severe course risk including treatments and other potential 
counfounders. 
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   Tab. 32 – Potential-outcome means (POMs) and Average Treatment Effect for the Treated (ATET) 
coefficients, p-values and odd ratios obteined by means of IPW for both treatments 
 
 
Tab. 33 – Standardized differences between the etoposide treated and not-treated groups before and 
after IPW for the included parameters. 
4.  Discussion 
In this work we aimed to apply a causal inference approach to the evaluation of prognostic 
biomarkers in sJIA-MAS. In order to investigate the causal pathways leading to unfavorable 
outcomes in these patients, we used theory and data-based graphical models that informed 
mediation analyses and variable selection for unbiased estimation of direct and indirect effect of 
measurable alterations at disease onset.   
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This allows to identify which, among factors that have been previously reported to be associated 
with increased risk, are causal determinants of outcomes and therefore possible targets of 
therapeutic interventions. 
Moreover, the causal analysis framework allowed for the exploration of specific treatment which, 
in absence of clinical trials, have not been empirically evaluated before. Directed acyclic graphs 
are valuable algebraic tools to distinguish causal from spurious associations by incorporating 
expert knowledge in the model. DAGs design require the a priori specification of plausible causal 
effects between variables of interest; although this introducing an inherent element of 
subjectivity in the analysis, it allows to expose transparently all the assumptions underlying the 
model.  
DAG-informed regression analysis demonstrated a causal effect of creatinine (AKI) and sodium 
levels on mortality, confirming our previous findings. Hyponatremia emerged as an independent 
risk factor, not explained by concomitant inflammation-driven Syndrome of inappropriate 
antidiuretic hormone secretion (SIADH) and AKI. We couldn’t directly assess a possible 
association with hypovolemic or distributive hemodynamic dysfunction (shock); however, 
mediation analysis evidenced no indirect effect due to heart failure (not shown) or multiple organ 
failure, which are frequent in similar clinical pictures.  
Despite not being identified as independent predictors, other biomarkers, such as AST and LDH, 
showed a non-linear association with death risk after adjustment with confounding variables; 
thus, although targeting this particular manifestations would not plausibly reduce mortality, they 
could provide useful prognostic information  when considering specific cut-offs.   
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Acute renal injury, as measured by creatinine levels, appeared the strongest determinant of 
death risk. This is in line with previous report of AKI as a predictor of poor outcome in HLH 
patients77. Many mechanisms have been proposed to explain the occurrence of kidney 
involvement in these forms, including histiocytic glomerular infiltration, direct cytokine-induced 
damage on glomerular epithelium, and coagulopathy-related disorders78. Microvascular 
thromboses of renal tissue79 have been demonstrated in patients with disseminated 
intravascular coagulation who develop AKI.  
To unravel the pathways leading to AKI and its association with mortality in MAS patients, we 
compared two possible pathophysiological models, one considering disseminate intravascular 
coagulation-like mechanism, the other involving thrombotic microangiopathy, by means of 
mediation analysis. Known differences in laboratory patterns associated with these two 
conditions were used to assess and compare the two explanatory models on data. We found that 
the TMA model, involving a pathway linking platelet decreasing with anemia, high LDH and 
bilirubin values due to supposed hemolysis, and renal injury was not supported by regression 
results.  Conversely, consumptive coagulopathy (increased d-dimer levels) exhibit an indirect 
effect on death risk through the association with kidney injury (high creatine); this suggest a 
causal role for DIC-like coagulative dysfunction in the development of life-threatening kidney 
involvement in these patients. Further investigations to clarify the mechanism behind kidney 
 
77 Santoriello, Dominick, Jonathan Hogan, and Vivette D. D’Agati. "Hemophagocytic syndrome with histiocytic 
glomerulopathy and intraglomerular hemophagocytosis." American Journal of Kidney Diseases 67.6 (2016): 978-
983. 
78 Karras, Alexandre. "What nephrologists need to know about hemophagocytic syndrome." Nature Reviews 
Nephrology 5.6 (2009): 329. 
79 Esmaili, Haydarali, et al. "An update on renal involvement in hemophagocytic syndrome (macrophage activation 
syndrome)." Journal of nephropathology 5.1 (2016): 8. 
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injury and other severe manifestations in MAS are needed to guide clinical decision-making in 
these patients, as the therapeutic approach is different in TMA80 and DIC-like abnormalities or 
full-blown DIC81. 
We found evidence that coagulopathy, as measured by fibrinogen levels, is also related to the 
development of CNS disease. This effect seems only partially (25%) mediated by the occurrence 
of clinical hemorrhagic manifestations. This complication appears more frequent in patients that 
were younger al MAS onset, although age was not confirmed as an independent predictor of CNS 
disease in this analysis. Interestingly, age at MAS onset also moderated the association between 
ferritin and CNS involvement, with younger patients already showing neurologic manifestations 
at lower ferritin values.  
The strongest determinant of CNS disease was creatinine, showing an OR of 2.4 (95%Cl 1.5 - 3.9). 
Around 18% of this effect is explained by the occurrence of AKI int the context of a more severe 
multisystemic dysfunction, as indicated by evidence of a mediation effect by heart failure.   
Similarly, creatinine was the main determinant of severe course (OR 1.8, 95%Cl 1.2 - 2.7). A non-
linear behavior is evident in this association, with higher probability of occurrence for levels 
above 0.7 mg/dl.  
 
80 Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, Cheung B, Machin SJ. British Committee for 
Standards in Haematology: guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura 
and other thrombotic microangiopathies. Br J Haematol. 2012;158:323–35. 
81 Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Scientific subcommittee on disseminated intravascular 
coagulation (DIC) of the international society on thrombosis and Haemostasis (ISTH): towards definition, clinical 
and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 
2001;86:1327–30 
140 
 
Hypofibrinogenemia emerged as another significant risk factor for severe course, underlining 
again the causal role of coagulative dysfunction in the development of unfavorable outcomes.  
Others parameter that didn’t confer a significant risk according to logistic regression analysis, 
such as ferritin, showed nevertheless a non-linear association with the outcome in MARS model; 
a threshold of 20000 ng/dl identified a clear increment in the risk of severe outcome. 
Although ferritin is generally considered a surrogate marker of histiocytic activation82, reflecting 
both IL-18 and IFNγ production, some authors have advanced the hypothesis of a mechanistic 
role of this molecule in feedforwarding the hyperinflammatory process in MAS and MAS-
predisposing conditions83.  
Consistently with a previous analysis84, non-linear models revealed also a correlation between 
higher age at SJIA onset and disease duration at MAS diagnosis and occurrence of a severe course. 
Patients above 11 years of age and with sJIA for more than 3 years appeared at higher risk; 
moreover, age at MAS onset, in particular for subject above 6 years old, correlated with the 
unfavorable outcome. However, these demographic features did not result independent 
predictors in adjusted regression models.  
Unsurprisingly, ESR, which resulted an independent predictor in our previous predictive analysis, 
did not show a significant association with severe course once adjusted for coagulation markers, 
 
82 Finch CA, Huebers HA, Cazzola M, Bergamaschi G, Bellotti V. Storage iron. In: Albertini A, Arosio P, Chiancone E, 
Drysdale J, editors. Ferritins and isoferritins as biochemical markers. Amsterdam, The Netherlands: Elsevier Science 
Publishers; 1984. 
83 Ruscitti, Piero, et al. "Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult 
patients affected by autoimmune disease: analysis of 41 cases collected in 2 rheumatologic centers." 
Autoimmunity reviews 16.1 (2017): 16-21. 
84 Minoia, Francesca, et al. "Dissecting the heterogeneity of macrophage activation syndrome complicating 
systemic juvenile idiopathic arthritis." The Journal of rheumatology 42.6 (2015): 994-1001. 
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confirming that the prognostic information conveyed by ESR just reflects the level of fibrinogen 
consumption. Interestingly, no effect on ESR values nor impact on outcomes were observed for 
Hb levels, conversely to what emerged from the previous analysis85.  
In the final part of the analysis, we addressed the causal effect of treatments on outcomes. Given 
the absence of validated evidence-based treatment guidelines on sJIA-MAS, treatment relies on 
expert knowledge and anecdotical reports86. Current management in pediatric rheumatology 
settings usually involve the use of corticosteroids and cyclosporine; increasingly, biologic agents 
such as IL-1 blockers are employed87. While not considered a primary approach in MAS, 
etoposide, a cardinal treatment for genetic forms of HLH, remains a therapeutic option for most 
severe cases88.  
Despite the non-randomized nature of our data, insights on treatments effects within the causal 
inference framework can be provided using inverse probability weighting89. By use of augmented 
IPW we obtained balanced samples of patients across treatment groups and found no evidence 
of a significant impact of etoposide and cyclosporine therapies on mortality.  
 
85 Minoia, Francesca, et al. "Dissecting the heterogeneity of macrophage activation syndrome complicating 
systemic juvenile idiopathic arthritis." The Journal of rheumatology 42.6 (2015): 994-1001. 
86 Boom, V., et al. "Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic 
juvenile idiopathic arthritis." Pediatric Rheumatology 13.1 (2015): 55. 
87 Behrens, E. M., & Koretzky, G. A. (2017). Cytokine storm syndrome: Looking toward the precision medicine era. 
Arthritis & Rheumatology, 69(6), 1135-1143. 
88 Ehl, S., Astigarraga, I., von Bahr Greenwood, T., Hines, M., Horne, A., Ishii, E., ... & Machowicz, R. (2018). 
Recommendations for the use of etoposide-based therapy and bone marrow transplantation for the treatment of 
HLH: consensus statements by the HLH Steering Committee of the Histiocyte Society. The Journal of Allergy and 
Clinical Immunology: In Practice. 
89 Halpern, Elkan F. "Behind the numbers: inverse probability weighting." Radiology 271.3 (2014): 625-628. 
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However, we couldn’t account for differences in the timing of treatment initiation, as temporal 
information was not included in the study survey.  
Also, due to the small number of treated patients in the dataset, which was collected between 
2002 and 2012, we couldn’t examine the impact of now widespread biologic therapies. 
Several other limitations must be acknowledged in the study, not only due to the retrospective 
and not-randomized nature of the dataset, but also regarding the absence of many not-
laboratoristic data, such as vital parameters, that could better explain and predict severe 
outcomes in acute settings. In particular, the analysis did not consider in the model important 
underlying pathogenetic factors, such as molecular biomarkers and cytokines levels, that are 
known to drive biomarkers abnormalities and clinical manifestations. A growing body of evidence 
demonstrated the key role of specific pathways, driven by IL-18 and IFNγ whose dysregulation 
strictly correlates with markers of hyperinflammation and organ involvement, including ferritin 
levels, white blood cell and platelet counts, transaminases and LDH.90 91 
However, as cytokine dosing were not object of the original study, we explored only the 
relationship between routine avaible laboratory parameters, which are plausibly influenced by 
multiple pathological processes. These unmeasured variables could have affected the nature of 
the DAGs and thus the results. The integration of organ damage markers and the cytokine 
networks underlying the immunopathological mechanism of MAS is warranted in further 
 
90 Shimizu, M., Yokoyama, T., Yamada, K., Kaneda, H., Wada, H., Wada, T., ... & Yachie, A. (2010). Distinct cytokine 
profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular 
emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology, 49(9), 1645-1653. 
91 Bracaglia, Claudia, Giusi Prencipe, and Fabrizio De Benedetti. "Macrophage activation syndrome: different 
mechanisms leading to a one clinical syndrome." Pediatric Rheumatology 15.1 (2017): 5. 
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research to develop an accurate, multilayered model able to inform a rational choice and 
prioritization of interventions, in order to improve the outcomes of this severe condition.   
Despite these limitations, these findings could have both clinical and research implications. The 
identifications of determinants of an unfavorable course could guide patient stratification and 
clinical decision making, increasing the awareness of relevant factors that clinicians need to 
target therapeutically to improve the outcome. From a methodologic point of view, our work 
highlights the limits of traditional analytic techniques in prognostic research where a complex 
interplay of variables is involved, and the potential of a causal inference approach in unraveling 
this network of effects.  
Conclusions 
Using a causal inference approach to explore the relationships between clinical features and 
outcomes in patients with sJIA-MAS, serum creatinine (OR 1.68, 95%Cl 1.11 – 2.50) and sodium 
values (OR 0.89, 95%Cl 0.82 – 0.96) emerged as main determinants of mortality. Mediation 
models supported a causal pathway linking coagulopathy to kidney injury and consequentially 
raised risk of death. Creatinine levels (OR 1.88, 95%Cl 1.29 – 2.76) were also the strongest risk 
factor for a severe course, followed by hypofibrinogenemia (OR 0.64, 95%Cl 0.48 – 0.84) and LDH 
(OR 1.34, 95%Cl 1.06 – 1.70). CNS disease was predicted by creatinine (OR 2.4, 95%Cl 1.5 – 3.9) 
and fibrinogen (OR 0.99, 95%Cl 0.99 -0.99) levels; ferritin levels (OR 1.59, 95%Cl 1.33 -2.15) also 
showed an effect on the risk of CNS involvement, which was moderated by age at MAS onset.  
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Chapter 5 – Development of a probabilistic prognostic model and score 
for sJIA-MAS 
 
1. Introduction 
Macrophage activation syndrome is a severe complication of systemic juvenile idiopathic arthritis  
(sJIA), belonging to the spectrum of hemophagocytic syndromes (HLH) characterized by a 
systemic hyperinflammatory process that underlies a wide range of clinical and laboratory 
alterations, potentially complicating with multiple organ dysfunction and eventually leading to a 
fatal outcome92.  
Despite the severity of this condition, the contributing factors to the development of outcomes 
in these patients are not fully understood. Very few evidences are avaible on prediction of 
outcomes in the HLH spectrum, and no prognostic tool for sJIA-MAS has been developed so far.  
The development of multiorgan failure, CNS involvement, anemia and age at onset of MAS older 
than 11.5 were found to be independent predictors of MAS severity93. However, the clinical-
laboratory features and organ involvements seen in MAS, including hyperferritinemia, 
pancytopenia, hepatosplenomegaly, hepatic dysfunction, encephalopathy and coagulation 
abnormalities, are not independent from one another, but are involved in a complex network of 
interactions and mutual influences. Previous analyses in the current work found evidences of 
nonlinearity and interactions between risk factors. Thus, more than the separate impacts of 
 
92 Ravelli, A., et al. "Macrophage Activation Syndrome." Handbook of Systemic Autoimmune Diseases. Vol. 11. 
Elsevier, 2016. 85-106. 
93 Minoia, Francesca, et al. "Dissecting the heterogeneity of macrophage activation syndrome complicating 
systemic juvenile idiopathic arthritis." The Journal of rheumatology 42.6 (2015): 994-1001. 
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single factors, a more effective modeling strategy could be that of incorporating the relationships 
among different factors in order to uncover the causal pathways through which the combined 
effects of multiple predictors determine disease outcome94.  
Bayesian networks (BNs) are a powerful tool that allow to depict the causal relationships 
between prognostic factors in probabilistic terms, generating quantitative counterfactual 
predictions for specific clinical scenarios that account for nonlinear relationships95. In BNs, the 
amount of information contributed from prognostic variables can be expressed in information 
theoretical measures, explicitly modelling the uncertainty in prediction96.  
In this study, we explored the potential of BN and information-theoretical measures to prioritize 
risk factors and develop a prognostic model for sJIA-MAS.  
For this task, we took advantage of the ability of BNs to incorporate prior knowledge in the model, 
using emerged insights from previous explorative analyses in this work to define the optimal cut-
off values for outcomes prediction.  
2. Methods 
2.1 Patients and data collection 
Retrospective patient data were gathered in a multicenter web-based survey involving pediatric 
rheumatologists and hemato-oncologists from 33 countries. To be included in the study, patients 
 
94 Thornley S, Marshall RJ, Wells S, Jackson R (2013) Using Directed Acyclic Graphs for Investigating Causal Paths for 
Cardiovascular Disease. J Biomet Biostat 4: 182. doi:10.4172/2155-6180.1000182 
95 Friedman N, Geiger D, Goldszmidt M (1997) Bayesian network classifiers. Machine Learning 
29:131–163. 
96 Si S, Liu G, Cai Z, Xia P (2011) Using Bayesian networks and importance measures to identify tumor 
markers for breast cancer. In Proceedings of the 2011 IEEE International Conference on Industrial Engineering and 
Engineering Management, Singapore. Piscataway, IEEE: 1826–1830 
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had to have SJIA and to have had an episode of MAS diagnosed by the attending physician; 
treatment had to be specifically altered to treat MAS. Demographic information such as age at 
MAS onset, age at onset of systemic JIA, duration of systemic JIA at MAS onset, as well as 
standardized laboratory values collected at disease onset  (defined as the time when the initial 
abnormalities suggesting the occurrence of MAS were detected) were included in the current 
analysis97. A detailed description of the cohort has been previously reported by Minoia et al98. 
2.2 Bayesian Networks 
Bayesian networks are a non-parametric formalism which models a network of interacting 
variables as a graph; the variables are represented as nodes and their interactions as directed 
links99. In other words, the edges in the network encode statistical dependencies between 
random variables. This representation allows to decompose the joint probability distribution of 
the variables into marginal probability distributions for the input nodes and conditional 
probabilities (CP) for other nodes. Thus, BNs can be used  not only to map probabilistic 
dependencies among predictors and outcomes, but allow for manipulating probabilities to draw 
inferences and  answer “what-if” questions, for which the answers are expressed as posterior 
marginal distributions for the other variables, conditioned on a user-specified set of values100. 
Another advantage of the method is that missing values can be easily handled. 
 
97 Minoia, Francesca, et al. "Clinical features, treatment, and outcome of macrophage activation syndrome 
complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients." Arthritis & 
Rheumatology 66.11 (2014): 3160-3169. 
98 Minoia, Francesca, et al. "Dissecting the heterogeneity of macrophage activation syndrome complicating 
systemic juvenile idiopathic arthritis." The Journal of rheumatology 42.6 (2015): 994-1001. 
99 Ben-Gal I. Bayesian Networks. In: Ruggeri F, Faltin F, Kenett R, editors. Encyclopedia of Statistics in Quality & 
Reliability. 2013. Chichester: Wiley and Sons; 2007 
100 Cox Jr, Louis Anthony, Douglas A. Popken, and Richard X. Sun. Causal Analytics for Applied Risk Analysis. 
Springer International Publishing, 2018. 
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Among the different algorithm developed to learn BNs from the data, the tree augmented naive 
Bayes (TAN), which accounts for dependence between variables, is proven to be superior for 
classification task and therefore has been used successfully in prognostic modelling101. This is a 
supervised data-mining method, where the researcher must select a target variable to be 
predicted. We accordingly applied a TAN algorithm to learn the structure and network 
parameters from the dataset for each of the outcome of interest – severe outcome, death and 
CNS dysfunction, including variables avaible at MAS onset, i.e. demographic features and 
laboratory values at diagnosis.   
As BNs only operates with discrete states, continuous variables were transformed into discrete 
intervals before computations. For emerged predictors, we used the results from previous 
analyses in this work to define the optimal intervals. For other parameters, a supervised 
algorithm was used to identify the most informative cut-offs.  
The TAN model was cross-validated 10-fold and the performance assessed through ROC curve 
analysis.  
Once the TAN model was estimated, in order to identify the most important predictors and 
strongest relationship, we examined the impact of different factors on outcomes distribution 
using measures drawn upon information theory, such as entropy, mutual information and 
Kullback-Leibler Divergence102.  
 
101 Banu, Bazila, and Ponniah Thirumalaikolundusubramanian. "Comparison of Bayes Classifiers for Breast Cancer 
Classification." Asian Pacific journal of cancer prevention: APJCP 19.10 (2018): 2917. 
102 Nicholson, Ann E., and Nathalie Jitnah. "Using mutual information to determine relevance in Bayesian 
networks." Pacific rim international conference on artificial intelligence. Springer, Berlin, Heidelberg, 1998. 
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Entropy (H) describes the expected amount of information that prognostic variable (X) contains, as 
defined as:  
 
where P(xi) is the probability of occurrence of X resulting in the possible value xi103. Maximizing the 
entropy equivales to maximizing the information content per observation104. 
Mutual Information (MI) is a measure of how much information is communicated, on average, in one 
random variable about another; in other words, it measures how much knowing one of these variables 
reduces our uncertainty about the other105. For example, if two variables are independent, knowing one 
does not provide any information about the other and vice versa, their mutual information will be zero.  
For two random variables X and Y, whose joint distribution is defined by P(X, Y ), MI is given by106  
 
Conditional mutual information (cMI) quantifies the expected value of the mutual information between 
two variables when a third variable has already been considered. Thus, cMI can be used to avoid 
information overlapping 107. 
A concept strictly related to MI is Kullback-Leibler Divergence (KL), or relative entropy, which measures 
how one probability distribution is different from a second, reference probability distribution108.For 
probability distributions P and Q of a discrete random variable, K is given by the the average of the 
logarithmic difference between the joint probability distributions P(i) and Q(i), where the average is taken 
using the probabilities P(i)109: 
 
103 Lee, Joon, and David M. Maslove. "Using information theory to identify redundancy in common laboratory tests 
in the intensive care unit." BMC medical informatics and decision making 15.1 (2015): 59. 
104 Delgado-Bonal, Alfonso, and Javier Martín-Torres. "Human vision is determined based on information theory." 
Scientific reports 6 (2016): 36038. 
105 Learned-Miller, Erik G. "Entropy and mutual information." Department of Computer Science, University of 
Massachusetts, Amherst (2013). 
106 Learned-Miller, Erik G. "Entropy and mutual information." Department of Computer Science, University of 
Massachusetts, Amherst (2013). 
107 Tsagaris, Vassilis, Nikos Fragoulis, and Christos Theoharatos. "Performance evaluation of image fusion 
methods." Image Fusion (2011): 71-88. 
108 Wikipedia contributors. (2019, December 13). Kullback–Leibler divergence. In Wikipedia, The Free Encyclopedia. 
Retrieved 14:33, January 8, 2020, from 
https://en.wikipedia.org/w/index.php?title=Kullback%E2%80%93Leibler_divergence&oldid=930573126 
109 Kullback, S. (1959), Information Theory and Statistics, John Wiley & Sons. Republished by Dover Publications in 
1968; reprinted in 1978: ISBN 0-8446-5625-9. 
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KL provides information on the differences between the probability distributions represented by the 
network with a specific link (i.e., a specific relationship between two variables), comparing to the network 
without this link; thus, it is useful to derive the contribution of each detected effect to the model.  These 
measures, thus, allow to rank prognostic factors by their contribution to risk prediction. 
 
We computed KL and MI metrics for each included variable. A sensitivity analysis was performed 
to evaluate how parameters vary in the condition that the value of prior probabilities varies. 
We then generated a decision tree to represent the hierarchy of the obtained prognostic criteria, 
based on entropy (or binary entropy) of the outcome node. The algorithm displays the optimal 
sequence of evidence that should be sought in order to gain the maximum amount of information 
on the state of the outcome of interest. The tree identifies distinct strata of patients with 
different probability of outcomes. reduction of entropy (information gain) provided by the 
variable provided by the combination of evidences. 
Based on the trained classifier, we implemented a decision support tool in the form of an online 
prediction system that provides probabilities of MAS outcomes according to user-provided values 
of predictors. 
Finally, to improve the usability of the results, a simplified numeric risk score for severe outcome 
and death was developed assigning to each predictor a weight based on a genetic algorithm that 
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takes in account the effects on outcomes and the evidences maximizing outcomes 
probabilities110.   
2.3 Statistical analysis 
Bayeslab (Bayesia Limited Company, France) was used to develop the BNs. Accuracy of the 
simplified score was assessed with the Jamovi software.  
3. Results 
3.1 Severe Outcome Model 
3.1.1 Structure and Parameters of the Bayesian Networks 
The structure of the Bayesian Network for severe outcome is depicted in Fig. 1. 15 predictors 
were linked to the outcome node, namely ferritin, LDH, fibrinogen, d-dimer, creatinine, BUN, 
sodium, neutrophil count, platelet count, ESR, AST, ALT, bilirubin, albumin, SJIA duration at 
disease onset. The relationship between AST, ALT and bilirubin were incorporated in the model. 
To assess the possible information provided by the latent clustering procedure reported in 
Chapter 2, we fitted a second dole including also the membership probability for each identified 
cluster. In the graph, a priori probabilities for each variable state (i.e., the distribution of values 
in the whole sample) are reported in each node.  The  
 
 
110 Conrady, Stefan, and Lionel Jouffe. Bayesian networks and BayesiaLab: A practical introduction for researchers. 
Bayesia USA, 2015. 
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Fig. 1- The structure of the BN for prediction of severe course. 
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Fig. 2 -The graphs show the probability of severe course for different values of each parameter. 
Histograms in Fig. 2 show the probability of severe course for different value state for each 
parameter. 
3.1.2 Importance ranking of prognostic variables 
The importance of prognostic factors was analyzed based on  
1) the total and direct effect on the outcome  
2) sensitivity analysis  
3) Information theoretic metrics  
3.1.3 Effects of variables on severe outcome: Which are the causal drivers of severe outcome? 
The total effect of each variable, which represents the impact of a small modification of the 
values of one variable on the outcome, considering the influence of the variable on every other 
node in the network, is reported in Table 1 and in the quadrant graph below. The positive 
impacts are displayed in blue and the negative ones are displayed in red. Fibrinogen, sodium e 
BUN levels emerged as the parameter with the highest impact on outcome.  
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Tab. 1 – Total effect of each predictor on severe outcome. Negative relationships are highlighted 
in red, positive in blue.  
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Fig. 3- the Standardized Total Effect displayed in the quadrant graph represents the Total Effect 
multiplied by the ratio of the standard deviation of the variable and the standard deviation of the 
outcome 
3.1.4 Sensitivity analysis  
Sensitivity analysis111 investigates the effect of small changes in parameter values (i.e., 
probabilities) on the outcome (e.g., posterior probabilities), computing a set of derivatives of the 
 
111 Castillo, E., Gutierrez, J. M. & Hadi, A. S. (1997). Sensitivity analysis in discrete Bayesian networks, 
IEEE Transactions on Systems, Man, and Cybernetics 27( 4): 412-423. 
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posterior probability distributions over each of the value states. Highly sensitive parameters 
affect the model more significantly. Conversely, If the derivative is small, even large changes in 
the parameter make little difference in the probability of the outcome112. In Fig. 4, sensitivity 
analyses for severe outcome and for both states of the outcome node are reported, with most 
sensitive factors, such as LDH, fibrinogen and BUN, represented in the top of the plot.   
 
 
112 https://support.bayesfusion.com/docs/GeNIe/bn_sensitivitybn.html 
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Fig. 4 – Tornado plots depicting the derivatives computed for each variable, expressing the 
influence of their variance on the model results 
3.1.5 Information theoretical metrics: Which are the most informative variables for severe 
outcome?  
A ranking of prognostic factors based on information theoretical indexes, such as MI, is reported 
in Tab. 2. The cut-off values (variable states) that provide the maximum information gain in 
forecasting the absence or occurrence of severe outcome are shown in Tab. 3 and 4. The 
relationship between variable values and their MI is represented in the quadrant plot (Fig. 5). 
Fibrinogen, LDH, BUN, Na levels exhibited the highest MI. The uncertainty on the outcome lowers 
with the cumulative evidence provided by these biomarkers, as show in Fig. 6. 
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Tab 2 – Information theoretical metrics for each predictor 
 
162 
 
 
Tab 3. and 4. – Information theoretical metrics of the predictors for each possible state (absence 
or occurrence) of severe course.  
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Fig. 5 – The Mutual information of each variable is plotted against its normalized mean value  
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Fig. 6 - The histogram shows how the probability of severe outcome increase by gathering 
evidence form the selected prognostic biomarkers. 
3.1.6 Target Dynamic Profile: Which combination of values are associated with the worst 
outcome? 
Tab. 5 and 6 report the combination of evidences that maximizes the probability of absence 
and occurrence of severe outcome, respectively.  
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Tab 5. – The combination of values with the highest the probability of absence of a severe 
outcome 
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Tab 6. – The combination of values with the highest the probability of occurrence of a severe 
outcome 
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Fig. 7 – target optimization tree for severe outcome. The tree identifies laboratory patterns 
associated with distinct probabilities of severe course 
The Target Optimization Tree in Fig. 7 describes sequence of observations associated with 
different probability of severe course. The combination of fibrinogen values < 115 mg/dl and Na 
levels < 131 mg/dl shows the highest probability (77,5%) of a severe outcome. The tree Is based 
on a numeric score for each variable, derived from a genetic algorithm, which is reported in Fig. 
8. The score is obtained by weighting the importance of the node, based on its effect on outcome 
and joint probabilities, and their position in the tree. In this way the score quantifies the 
relevance of specific predictors values. Evidences with the highest score are those associated 
with the highest probability of the outcome.   
 
Fig. 8 – Optimization score for the most predictive values for severe outcome 
 
3.1.7 Accuracy assessment 
We evaluated the accuracy of the TAN and its performance through the AUC (c-index) of its ROC 
curves.  The model for severe course achieved a c-index of 0.828. Adding the obtained latent 
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clusters to the BN model increased only slightly the prediction accuracy, up to a c-index of 0.834. 
Accuracy metrics and ROC curve of the basic model is reported in Fig. 9 e Tab 7.   
Fig. 9 – ROC curve for the occurrence of severe outcome 
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Tab 7 – Accuracy indexes for the ROC curve for severe outcome.  
 
 
 
 
 
 
3.2 Mortality model 
3.2.1 Structure and Parameters of the Bayesian Networks 
The BN graph for mortality prediction is shown in Fig. 10. Ferritin, triglycerides, LDH, sodium, PLT, 
neutrophil count, creatinine, BUN, albumin and fibrinogen levels resulted predictive of death risk. 
The probability of fatal outcome depending on different values of the prognostic variable are 
reported in Fig.11.  
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Fig. 10 – The structure of the BN model for mortality prediction 
172 
 
 
Fig. 11 – Histograms showing the probability of death according to the values of each predictor  
3.2.1 Importance ranking of prognostic variables: 
Effects of variables on mortality: Which are the causal drivers of fatal outcome? 
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As reported in Tab. 8 and Fig. 12, serum sodium, triglycerides, creatinine and BUN values had 
the highest effect of mortality.  
 
Tab. 8 – Total effects of the different risk factors on mortality 
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Fig. 12 – Standardized total effect of each variable, normalized for its mean value 
3.2.2 Sensitivity analysis 
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Fig. 13 and 14 show how the probability of death highly depends on difference in Na, creatinine 
and triglycerides values.  
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Fig. 13 and 14 – Tornado plots of both state of the outcome (Fig 13) and for death (Fig 14) from 
sensitivity analyses in the model for mortality 
3.2.3 Information theoretical metrics: Which are the most informative variables for 
mortality?  
As highlighted in Tab. 9 and Fig. 15, serum Na concentration shows the higher mutual 
information, followed by PLT and triglycerides levels.  
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Tab. 9 – MI for each variable in the mortality model  
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Tab. 10 – MI for each variable in the mortality model for each outcome state 
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Fig. 15 – MI for each variable, according to mean values, in the mortality model  
3.2.4 Target Dynamic Profile: Which combination of values are associated with the highest 
probability of death? 
As shown in Tab. 11 and in the target optimization tree for mortality, the laboratory pattern 
that show the highest probability of a fatal outcome is defined by BUN, Na, PLT, fibrinogen, 
albumin, ferritin and triglycerides values. Sodium levels above 131 mg/dl are associated with an 
elevated (95,76%) probability of survival. The target optimization tree reporting different death 
probabilities according to the combination of specific evidences and the corresponding 
optimization score are reported in Fig. 16  
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Tab. 11 – Optimized laboratory profiles that identify the maximum probability of survival and 
morrtality 
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Fig. 16 – Target Optimization Tree and optimization score for the mortality model  
 
3.2.4 Accuracy assessment 
The model for mortality showed a mean ROC index of 0.816. A difference in the ability of the 
TAN to forecast the occurrence of death ore survival was observed, with a higher ROC index for 
death (87.6%) than for survival (75.6%)- ROC curves and accuracy metrics are reported in Fig. 17 
and Tab. 12. 
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Fig. 17 – ROC curves for mortality prediction 
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Tab. 12 – Accuracy of the mortality model 
 
3.3 CNS disease model 
 
3.3.1 Structure of the Bayesian Network  
As represented in Fig. 18, the model for CNS involvement retained 15 predictors, including age 
at SJIA onset and disease duration at MAS diagnosis.  
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Fig. 18 – The structure and value distributions of the BN for CNS disease 
3.3.2 Importance ranking of prognostic variables: 
Effects of variables on mortality: Which are the causal drivers of CNS dysfunction? 
Total effects of variables on the probability of CNS disease are reported in Tab.13 and Fig.19. 
Fibrinogen, creatinine and BUN exhibit the greatest impact.  
 
Tab. 13 – Total effects on CNS disease  
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Fig. 19 – Standardized total effects of each predictor on CNS disease  
3.3.3 Sensivity analysis 
As depicted in the tornado graphs (Fig. 20) AST, Na and creatinine values emerged as the most 
sensitive parameters in the model for the prediction of CSN disease.  
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Fig. 20 – Tornado graphs resulting from sensitivity analysis of the CNS model 
3.3.4 Information theoretical metrics: Which are the most informative variables for the 
prediction of CNS disease?  
Ferritin, fibrinogen, LDH and creatinine levels are the variables providing the higher information 
gain in forecasting the occurrence on CNS dysfunction (Tab. 14 and Fig. 21)  
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Tab 14. – MI of each variable for different outcome status 
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Fig 21. – Binary MI of each variable according to mean values 
3.3.5 Target optimization: Which are the combinations of values associated with the highest 
probability of CNS disease?  
Tab 15 shows the laboratory pattern at highest CNS-risk, characterized by hypofibrinogenemia 
and hypoalbuminemia.  The target optimization tree and relative optimization score for CNS 
involvement are reported in Fig. 22.  
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Fig. 22 – Target optimization tree and score for CNS disease prediction  
3.3.6 Accuracy assessment 
The model for CNS disease reached a c-index of 0.816, with a slightly worse curve for the 
absence of the outcome (Fig 23)  
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Fig. 23 – ROC curves and accuracy indexes of the CNS disease model  
4. Online prediction system for MAS outcome 
Based on information theory metrics (conditional mutual information) from the BN model, a 
decision algorithm for the prediction of severe course was implemented and transposed in a 
web-based decision support tool for external users. Outcome probabilities predictions are 
provided in real time according to the predictor values entered by the user. The prediction system 
is freely accessible at https://simulator.bayesialab.com/#!simulator/130366133559. Figure 24 
shows a screenshot of the tool.  
Fig. 24- Screenshots of an online prediction system for severe course in sJIA-MAS. The left-hand 
pane allows for entering predictor values for a given patient case, while the right-hand pane 
shows in real-time the associated probability of outcomes, according to the embedded TAN 
model. 
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5. Discussion 
In this work we integrated our previous results to develop a prognostic model of sJIA-MAS in a 
probabilistic and causal inference framework, through the use of Bayesian Networks and 
information theoretic metrics. Bayesian network are powerful formalism to capture the 
complexity of the interrelationships between various biomarkers, representing dependency 
between causes and effects, and can account for the inherently uncertainty of the prognostic 
process in terms of probabilities, quantifying the risk in the form of probabilities113. Among the 
other advantages, BNs provide a visual and understandable way to represent the relationship 
between variables though an inference process that is more interpretable than most machine-
learning based predictions, as it mimics human decision-making. Their potential in measuring 
risks under uncertainties has promoted their employment in different diagnostic and prognostic 
research114 115 116.  
Besides assessing the impact of single variables on the outcome, BNs can analyze how predictors 
are related to each other. This allows to simulate various scenarios and calculate the changes in 
outcome probabilities associated to a specific laboratory pattern, i.e. a combination of risk 
factors.  
On the other hand, information theoretical measures allow to quantify the uncertainty in 
outcome (entropy) both prior to and following a laboratory test, providing a measure of the 
 
113 Lucas, Peter. Bayesian networks in medicine: a model-based approach to medical decision making. na, 2001. 
114 Langarizadeh, Mostafa, and Fateme Moghbeli. "Applying naive bayesian networks to disease prediction: a 
systematic review." Acta Informatica Medica 24.5 (2016): 364. 
115 Sesen MB , Nicholson AE, Banares-Alcantara R, Kadir T, Brady M. Bayesian networks for clinical decision support 
in lung cancer care. PLoS One. 2013;8(12):e82349. 
116 Cai ZQ , Si SB, Chen Cet al.  Analysis of prognostic factors for survival after hepatectomy for hepatocellular 
carcinoma based on a Bayesian network. PLoS One. 2015;10(3):e0120805. 
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information gained by accumulating evidences117. For this reason, information theory has been 
employed in different clinical contexts and applied to the evaluation of laboratory data 118. 
What emerged by  BNs models and mutual information based algorithms is that 
hypofibrinogenemia , as well as hyponatremia and alteration of markers of kidney injury, namely 
creatinine and BUN, are the risk factors that have the highest impact on most severe outcomes 
and provide the greatest amount of information for the prediction of a complicated course and 
death. This is in line with previous evidences on the prognostic value of renal involvement in the 
HLH syndromes119, and with results of our previous subgroups and causal analysis that employed 
regression modelling techniques.   
A prognostic role, not previously highlighted, was demonstrated for LDH and triglycerides high 
levels, respectively for the forecasting of severe course and fatal outcomes, whose value as risk 
factors need to be investigated in further works.  
Among other predictors, the current analysis confirmed the non-linear hazard conferred by 
ferritin values which, albeit not a causal driver of outcomes, becomes highly informative for the 
prediction of both severe course and CNS involvement above levels of 13000 ng/dl.  
The model showed a good forecasting performance for all the outcomes. To allow for querying 
of the model in specific clinical scenarios, these results were embedded in an interactive web--
based prediction system, avaible for external users, which is based on information theoretical 
 
117 Lee, Joon, and David M. Maslove. "Using information theory to identify redundancy in common laboratory tests 
in the intensive care unit." BMC medical informatics and decision making 15.1 (2015): 59. 
118 Vollmer R. Entropy and information content of laboratory test results. Am J Clin Pathol. 2007; 127:60–5 
119 Karras, Alexandre. "What nephrologists need to know about hemophagocytic syndrome." Nature Reviews 
Nephrology 5.6 (2009): 329. 
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measures. Traditional risk scores usually use coefficients from regression modelling to derive the 
risk weights for predictors. This, however, allows to account only for the individual relationship 
between the variable and the outcome in a linear way, ignoring the interrelationship among 
predictors. Other authors120 121have developed Bayesian Network-based risk score for different 
conditions, generally showing an improvement in accuracy or usability compared with the 
original regression-based scores.  In this study, we used the information encoded by the BN 
model on the effect on outcome for the key predictors and the information gain from each 
evidence, as calculated by the optimizing algorithm, to develop a BN-based simplified risk score. 
In this way, we aimed to incorporate in the score the probabilistic associations between variables. 
The score reached a decent c-index for severe outcome and showed a good accuracy for the 
prediction of mortality, outperforming the performance of the regression and CART modelling 
presented in Chapter 3.  
Among the limitations of this study is the retrospective nature of the dataset. Second, the effects 
of treatments were not considered in this analysis. Moreover, we argue that for a comprehensive 
causal analysis of this syndrome, the inclusion of cytokine and immunologic mediators that are 
known to drive the pathogenesis of HLH/MAS is crucial. Although molecular and cytokine data 
were not avaible in this dataset, one of the advantages of the Bayesian Network formalism is that 
the model can be easily updated with further evidences, refined with expert knowledge and 
merged with evidences from independently performed but related studies. The integration 
 
120 Loghmanpour, Natasha A., et al. "A new Bayesian network-based risk stratification model for prediction of 
short-term and long-term LVAD mortality." ASAIO journal (American Society for Artificial Internal Organs: 1992) 
61.3 (2015): 313. 
121 Kraisangka, Jidapa, Marek J. Druzdzel, and Raymond L. Benza. "A Risk Calculator for the Pulmonary Arterial 
Hypertension Based on a Bayesian Network." BMA@ UAI. 2016. 
200 
 
between routinely gathered laboratory parameters and cytokine levels could allow to estimate 
the probabilities of the latter in clinical context where they are unavailable, allowing for the 
identification, in probabilistic terms, of the most appropriate cytokinin target to address 
therapeutically, based on specific laboratory patterns. The potential demonstrated by this 
methodology encourages the validation and expansion of our analysis with a prospective and 
more complete data.  
6. Conclusion 
In summary, the combination of Bayesian networks and constructs from information theory 
allowed to identify the key determinants of sJIA-MAS outcomes. This study could represent a 
proof-of-concept showing the potential of this methodology in the context of complex disease 
like HLH/MAS. These results could help refine our approach to patient management, monitoring 
and stratification in MAS, to raise the awareness of mechanisms that drive the progression of 
MAS to unfavorable outcomes, and to rationally choose the most appropriate 
immunosuppressive and supporting therapies to improve the outcomes.   
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-Target interpretation tree for the prediction of mortality based on mutual information  
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-Target interpretation tree for the prediction of CNS disease based on mutual information  
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Conclusions 
Macrophage activation syndrome is a fearsome complication of many autoimmune conditions, 
particular associated to Systemic Juvenile Idiopathic Arthritis. The clinical and laboratory 
spectrum of its manifestation is wide, encompassing dysfunction of different organs, and the 
highly heterogenous in its severity. The course of the disease can be unpredictable, in some case 
rapidly evolving in multi organ failure and fatal outcome. Recent research efforts have focused 
on improving the accuracy and promptness of diagnosis, through the development of diagnostic 
criteria. However, despite the recognized severity, prognostic research on this condition is still at 
an early stage. To get insights on the dynamics of disease progression and discover which risk 
factors can help predict poor outcomes at disease onset, we combined subgroup analysis, 
regression modelling and Bayesian methodology within a causal inference and probabilistic 
framework for the analysis of a large multinational cohort.  We identified selected laboratory 
alterations at MAS onset, among the test that are routinely obtained in these patients, which are 
surrogate for the most probable determinants of disease progression toward unfavorable course 
and are most informative for outcome prediction. Based on these findings, we developed a 
probabilistic prognostic model for sJIA-related MAS that is able to forecast with a good accuracy 
the clinical evolution of these patients and provides personalized predictions through a web-
based predictive tool. Further research is warranted for the validation of these results and the 
expansion of the model with further predictors that can improve its performance. These findings 
add to the current understanding of MAS and, through a better stratification of patients and 
identification of appropriate targets of clinical monitoring and treatment, can help improve the 
outcomes of this complex and severe condition.    
206 
 
Acknowledgements 
 
I would like to thank my supervisor, Prof. Angelo Ravelli, for the opportunity to conduct this 
research and PhD programme. I would like to express my gratitude also to Dr. Nicolino Ruperto 
for supporting my interest in methodology. A special thank goes to Dr. Alessandro Consolaro for 
his fundamental support and guidance during my doctoral years. Thank you to all of my 
colleagues and PRINTO research assistants.  
I would also like to remember here Aaron Swartz and Alexandra Elbakyan, whose works made 
this research, as well as many others worldwide, possible.  
Lastly, I would like to thank my parents, my sister Alessia and Luke.  
 
 
